Adi Robinson, PhD, DABR
Medical Physicist
AdventHealth Celebration, USA

Transcript

I’ll be talking today about one of our trials that we’ve started recently about maskless head and neck treatments.

Our disclosures are: we’re a center of excellence for AlignRT, for Vision RT, but none of that is reflected here. It’s all independent research and no financial motivation. So, as you all know a little bit about Central Florida and AdventHealth in Central Florida, Central Florida is awesome. Look at all the many fun things that we can do. But we have about 15 radiation oncology centers, 25 LINACs, two Halcyons, one gamma knife, three HDRs, 12 AlignRT systems—and I think that number is just growing thanks to Kenny—and two Invor systems, three SimRT systems, and currently just one MapRT and one DosRT.

One of our sites in Celebration here has the complete workflow from simulation all the way to treatment and treatment verification, and I think it revolutionizes our workflows. Some of it we’ll see in this talk, and some of it you’ll see in other talks from Mike and Anton on how we implemented SGRT in every step of the workflow.

But coming back to our topic, treating head and necks is difficult. Part of the difficulty comes from the anxiety. Mask anxiety is a big problem, and a few of the papers that I looked at quickly said that 43% of patients report significant anxiety before the mask fitting. So, you take them into simulation, they see that big thing that’s going to go on their face, and that’s kind of where the panic starts. Twenty-six percent of the head and neck patients report mask anxiety during and before, and you have a range of 14% to 58% of head and neck treatments that experience some sort of level of mask issues to the patient.

And how does that impact us? You can get treatment interruptions because the patient can’t handle it and needs a break, so you have to take off the mask, extend your treatment time, give them a break, put the mask back on, and try to continue, which interrupts the patient and could cause delays either in delivery of that fraction or even delays of the full fraction. Some of them will abandon treatment midway or not even start. It’s really a reduction of quality of life during their treatment; they’re already battling a terrible disease, and we’re just adding more complexity and suffering. Some of us have to rely on anxiety medication and other stuff—again, an unnecessary barrier to cross.

The traditional approach that most clinics probably use is a closed-face five-point head and shoulder mask. It’s a thermoplastic mask; it’s rigid. It gives you a very reproducible setup but introduces a lot of anxiety and claustrophobia, and you cannot use SGRT on that treatment—you’d have no valuable surface there.

Alternatives have come as SGRT became more popular in the form of an open-face mask. There are two versions: I’m showing a three-point mask here, but you can also get the shoulder one, so it’s a five-point mask with an open face. That improves mask tolerance in a sense that the patient can tolerate it more. It enables SGRT monitoring, yet you have a very small real estate volume there. It still confines your face—your mouth is really close to your nose—and it could still confine your breathing. But it has comparable accuracy to a closed-face mask, so the reproducibility is still pretty good.

The proposed approach is a fully maskless treatment and SGRT implementation—a full contactlessly experience. You can use six-degree-of-freedom monitoring using SGRT. You get only dorsal shell support, so only the bottom of the neck and head is supported. And you can add automatic beam hold: if you set a tolerance and the patient exceeds that, it will automatically hold the beam for you.

Our key study question is: can we eliminate rigid facial immobilization without compromising accuracy and patient safety? So to enable that, we have to think about a few things. We need surface tracking. We need a modality that can track six degrees of motion in the patient during setup—because we need an accurate setup—and during delivery. We need something to continuously monitor the patient; if the patient is going to move during treatment even slightly, we need something to tell us. When it tells us, we don’t want a delayed reaction; we want something to automatically hold that beam. And with all that, we want to enable that contactless, free experience.

The way to do it is to go from that traditional approach all the way to the SGRT approach. This dorsal shell experience—and I’ll tell you what we’re using—is just one example. Mike Thalhammer in AdventHealth Denver uses just an AccuForm for the shoulders and the head to basically produce that. So whatever kind of works for you, you can customize your SGRT workflow to do a maskless head and neck like that. That’s the flexibility and advantage of using an SGRT system.

Our objectives were to look at four things. We wanted to look at interfractional accuracy: determine whether the maskless workflow, using SGRT, maintained sub-millimeter interfractional accuracy or close to it. We were going to use SGRT versus IGRT validation, looking at SGRT measurements throughout the fraction, comparing our imaging to it, and seeing if they agree. We wanted to see if it made our workflow better, the same, or worse; did it take us longer to treat that patient, or was it smooth as if they were masked? And patient comfort is key here—a metric that is hard to do, especially if they did not choose the masked approach, but an assessment of how they feel and how they’re doing is important.

The patient selection criteria were set early on. We were obviously looking for head and neck patients suitable for conventional fractions who were able to maintain head stability, willing to participate, and approved by the physician. We don’t want people with head tremors or cognitive impairment where they can’t listen to directions. I kept my options open if they really preferred a mask, but for the 10 patients that we had in the study, we showed them both options, and they all picked the maskless option.

I will say that when I pitched this project to our head and neck physician and explained that I wanted someone who could follow directions and stay still, he came back with a list of patients who all had claustrophobia and anxiety. They were the opposite of what I asked for, but that’s how it is because those are the patients that need this workflow the most. It’s a blessing in disguise; if we can prove that this works in that cohort, then the other cohort will be easy.

Our general setup strategy: we used the Macromedics DSPS Prominent Dorsal Shell for our immobilization. We set them up using AlignRT and postural video, and then CBCT. We monitored them again with AlignRT with three degrees of motion. Our internal thresholds were set to two millimeters and two degrees. We did a post-CBCT verification for residual displacement—on some patients daily, on some weekly. We did our evaluation comparing what we saw in SGRT to what we saw on IGRT and plus more.

ROI selection was trickier because we needed something to mimic a mask so we could monitor the patient, so we came up with a three-tier ROI system. We started with four, narrowed it down to three: shoulders, face, and a treatment ROI. The reason why we have a separate shoulder ROI is because the rotation axis of your body is a different axis of rotation for your shoulders and neck than your face. We set them up to the bigger ROI, switch to the little ROI for fine-tuning, then go back to the big one to make sure it looks good, then switch to the treatment ROI, and treat.

We knew patients like to track the gantry with their eyes or blink or lick their lips, but it was never a problem in a masked workflow; now it is a big problem, so we’ve learned to cut that out. We exclude the lips and eyes because we’re not confined by a mask anymore. We have a lot more real estate, so we can expand it and exclude the stuff we know they’re going to move. We just have to keep in mind to add enough lateral ROI so during the arc delivery, both cameras can detect motion in six degrees.

Our results: we have a mean interfraction translation of one millimeter throughout all our translational axes and 0.9 degrees throughout our rotation axes. Our residual translation for post-CBCT was about half a millimeter, so we know they did not move from initial to post-CBCT. We had about 10% of patients with at least one threshold violation, but only 4% required repositioning. The maskless workflow actually proved to be more rigid because patients were less irritated and moved less.

Patient experience was 100% positive; none of them said they would want to be treated with a mask. Threshold violations are more frequent with maskless because of that freedom, but AlignRT covers us. Regarding treatment interruptions: again, more with maskless, but easily rectified. None of these cases were treated over our normal 15-minute time slot.

Because we have DoseRT and Cherenkov imaging on site, I’ll slide in this slide for fun: on your left is a surface dose from Eclipse, and on the right is the patient being treated. There’s no mask; he’s just laying there in his dorsal shell, closing his eyes, concentrating on staying still. We see the dose went where it’s supposed to go—it’s another form of verification.

Looking at a patient’s journey: one patient with a tonsillar malignancy, 70 Gy, 33 fractions. He lays on the dorsal shell, and we carve it around his shoulders and neck. The DSPS system can come in two ways: it can be a clip-on to your normal S-frame, or a standalone board. Our absorption studies on the additional carbon fiber frame showed it’s insignificant. After we created the VMAT plan, set up the patient, and got the real-time deltas green, postural video served as our virtual mask to ensure shoulders and head were in the correct place.

One statistic I wanted to finish with: we’ve had patients who said they would rather die than be treated in a mask. Our first patient was so scared he didn’t even want to get scanned in the CT. Since he was the first, I was present for most of his fractions, and you could see him after the first week—he would jump on that table and was happy as a clam. At the end, he basically said we saved his life because he wouldn’t have been able to be treated otherwise.

To wrap everything up: it’s clinically feasible—actually, it’s amazing—to treat with an open-face mask using AlignRT. You have active safety delivery with automatic beam hold. You get millimeter accuracy and a universal patient experience; we can offer this to anybody, claustrophobic or not. For the patients, it’s a super valuable addition to our tool chest. For our therapists, I didn’t change their workflow one bit. The physics part requires some commissioning work and validation to maintain that high level of accuracy, but other than that, it’s not too much. I have to say thank you to Mike and my team at Celebration for helping. Thank you all.

 

 

*This transcript has been AI-generated. Contact us at secretary@sgrt.org if there are any issues.

Sally Eggleston, MBA
COO
Radiation Business Solutions, USA

Transcript

I’m Sally Eggleston. I work for Radiation Business Solutions. I’ve probably talked to quite a few of, if not you, somebody in your system. We assist Vision RT’s customers with reimbursement questions and payer problems. We’ve been in the business over 22 years with radiation oncology. It is our passion. It’s what we do. We’re a full revenue cycle, but we like to help people. We own and operate and manage centers also, so we understand the pains and what you guys go through on every day, and radiation oncology is really at a very important time right now. So one of the things you will hear me preach is continue to fight and work with these payers.

Just a small disclaimer: your practice is your practice. You need to do what you feel right and document the heck out of everything. So this is what happened to us in 2026. These are the descriptors. When you look at 77412, it specifically says there are different caveats. There’s either multiple isocenters, or the single isocenters with active motion management, which is what a lot of what we’re talking about today, or total skin, or mixed electron photon. So one of the things that I’m going to talk about here shortly is about the fact that there are so many variables that are in there. And this is the payment rate that we’re looking at. The top is the Medicare physician fee schedule, which would be freestanding, and below that would be the hospital outpatient. And you can see that there are definitely discrepancies in there, and that’s one of the things that we’ve got to get addressed.

Probably one of the surprisingly biggest issues that we hear people talking about is this 77387, and I don’t really understand it, but hospitals and coders are really having a problem with that from the standpoint of, they don’t understand it. They don’t believe it’s still billable. They think it is packaged in the treatment delivery, which it is on the technical side, but it’s not on the professional side. Your physicians should be billing the 77387 if they are doing anything such as cone beam CT, SGRT, and looking at images, stereoscopic, any of those. So, if you’re having issues with your system or somebody with that, please reach out to us because that is craziness for our physicians to not get RVUs and payment for that code on a daily basis.

So some of the common questions we see are that, can we do it? Yes, you can. Let’s get that one going. Active motion management: whenever those CPT codes had the new descriptors, the first thing we did was look at what the AMA’s and the CPT definition was, and if you read that, it clearly states surface guidance in there. It says, example: intra-fraction motion, surface guidance to monitor the target or organs at risk during the breathing cycle. Example: it minimizes organ motion, allows more accurate delivery to mobile targets. It’s a technique that can provide gating using the body surface contouring as a surrogate for internal target motion, using the surface as a surrogate for internal motion. So that solidified to a lot of people like Dr. Jones and to us as we read it, that surface guidance is in the descriptor. It accounts for active motion management. It is billable under the 77412.

I’m not going to talk a lot about medical necessity because Dr. Jones did an amazing job with that. That is always the case. Documenting medical necessity from the physician’s standpoint—I can’t tell a physician how to treat a patient. None of us can in here. Only a radiation oncologist makes that decision. So it is up to them to document why they are doing active motion management with whatever technology they’re utilizing, and in this case, SGRT, through Vision RT. So, those orders must be in there, and a lot of this when it comes to commercial payers, is about that documentation and what you say to get your authorization, and we’ll talk a little bit about payer issues in a minute. So it does need to be patient-specific. You can have a rather canned paragraph, but dropped in patient-specific information is strongly encouraged.

And the patient must be monitored during beam-on. Surprisingly, we still get asked that question, too. So it’s not about setup, it’s about monitoring during beam-on, and we just had the conversation; that was straight from Emilio from ASTRO, who is really championing on the coding side for all of us that surface guidance does qualify for active motion management under 77412. There’s that question over and over again. Yes, it does. It’s one of several. So that’s the other thing, right? I’m on an island here. It’s not just one technology, it’s more than one. They’re very clear with that. But Vision RT definitely hits the mark.

And this utilization question continues to come up. You just heard what Dr. Jones’ was. And the way the utilization—the reason that comes up—is because in the proposed rule and in the final rule, there were percentages of how much percent of the Level One, Level Two, and Level Three treatment delivery that was expected. And they do that because they have to do that because there’s just one bucket of money for everything under the Medicare physician fee schedule, and they have to allot these dollars of how they think it will work, and that’s how they decide on payment. And that’s why we saw payment fluctuation from the proposed rule to the final rule.

So those percentages are in there because of that, but does that mean that’s what you should do or where you should be or that you should worry about that? And our response to that is always no. And when I read that 77412 descriptor, how would they even know if you were a center in a rural area who treated 50% of their patients with bone mats that have more than one isocenter versus you doing surface guidance, active motion management, right? A payer’s not going to know that. CMS is not going to know that. So their data mining of utilization is going to be all over the place strictly because of the wording in that descriptor. So, keep that in mind. It’s difficult whenever there has to be a decision tree for you to make for your therapist to figure out what code it should go to, right? At the very beginning, that’s what we utilized. It worked well, but that’s craziness, right? That’s where we end up having to do.

We do have resources for Vision RT customers to help you on the authorization side, appealing a claim. Radiation oncology has to stick together right now. This is not the time to roll over or allow your physician to say, “EviCore, I don’t want to do a peer-to-peer.” This is not the time to do that. We’re really at a crux here. It’s not just the freestanding centers that are feeling this, but hospitals also. So it is definitely the time to band together.

When it comes to these codes, it’s difficult, and somebody asked the question, have you got any Medicare denials? Medicare is going to pay you most of the time for whatever code you send through. They don’t know what you did. It is an honor system, right? Which is why you document thoroughly. It’s why you put everything out there. Make sure that you’ve ordered medical necessity and you’ve documented what you’ve done. If Medicare does anything, it’s on the back end and they may say, they periodically look at a center and say, “We need 10 medical records to prove that you did this.” CERT audits and those type things.

When it comes to the commercial payers, different story. So because in the freestanding centers we had been utilizing G-codes for over 10 years, right? We’d been using G-codes for a long time. So in November, we’re calling commercial payers and saying, “We want to make sure you’re prepared. We’re going to not be billing these G-codes.” These are old CPT codes. They’re not new. I used these a million years ago. Dr. Tannahill’s talk really spoke to me yesterday because I’ve been saying that for a long time. We’re totally flipping back to the old school days, right? So when you have CPT codes that have been on a commercial payer’s fee schedule for a really long time, they just keep lowering what that payment rate is. And so what happened come January, yeah, they’re processing your new CPT codes, but the rate is really low. So there’s been a lot of battles to fight. There’s been updating your fee schedules.

The Medicaids, and I kind of laugh about this, and I’m not poking fun at ACRO, don’t think I am, because we work with ACRO and ASTRO to make sure that they are advocating on our behalf all the time. They put this list up on a webinar that they had last week. There were some duplicates on there. Well, this is how many payers and the states that they had been working with. We’re a revenue cycle company that has been in the business for 22 years. So we looked at our system. We had 741 payers in there. That’s a lot, right? So, this has been our problem. Freestanding centers, a lot of times, don’t have the manpower to go to those commercial payers, make sure the fee schedules get updated. Hospitals don’t pay attention, frankly. Right? So, sorry, but that’s the reality of the revenue cycle side in a hospital. And it’s really important right now for hospitals to be adjusting their charge master with these codes. Because that utilization, what the cost is, goes to Medicare, and we got to make sure we have that part right.

So there’s still a lot of work to be done. Every Medicaid in the United States has got a letter from ASTRO and ACRO and from us, and any place we have a client, we’re sending letters to the governors, to state officials, because Medicaids are state-run, and they’re not wanting to pay for these codes because they don’t know what to do with it. I’m not quite ready for questions. I just wanted to throw out, ASTRO did have a town hall Wednesday night. It was supposed to last an hour and a half. It just lasted an hour 15 minutes. It was pretty low-key. They explained what happened, what they’ve been doing, everything from their Hill day last week to working with payers to trying to get a fix or a change. I’ll be blunt, it doesn’t look promising. And the reason being because come July, our proposed rules are going to come out, and it’ll be interesting to see where our payment rates lie there. They did say very specifically, because somebody asked, “Are prostate patients 77470 level two?” The answer was yes. And then another physician on ASTRO chimed in and said, “But we need to keep in mind that if they have the technology and can provide active motion management, that they are 77412.” That came out of their mouths. Everybody heard it. Unfortunately, there was at the max, 110 people on that Zoom call, which is very disappointing to me for this industry. There again, now’s the time. We’ve got to band together. We’ve got to advocate.

The other thing that they stated on there was that they will be putting out a policy, but it probably will be the summer, which is rather unfortunate that we get the policy July, August. I figure they’re probably waiting a little bit for the proposed rule to come out there, too. But that was the latest and greatest from them. It solidifies what we and Vision RT have been telling their customers. That goes right along with what Dr. Jones said. If you have the medical necessity from the physician, you’re documenting it, then bill your 77412, your level three.

On some payer notes, UHC, they’re difficult. That’s just all there is to it. They are still wanting to deny a lot of prostate and brains, and we’re talking about getting the authorization up front. But they definitely deny for the first level, and you have to move on and keep fighting, which you can have a bit of success. eviCore did publish guidelines, so they become pretty clear. They consider peer-to-peer outside of anything that’s not on their covered diagnosises. ASTRO worked with them in early January on that, and most of the time, we can get 77412 approved outside of their diagnosises today. Carelon, which is a radiation benefit management company, all body areas are okay for 412, but based on individual plan guidelines, so you may have to argue some of those. Evolent denies head and necks, and their medical director told us that they have been instructed to deny prostate. So I don’t know, Dr. Jones, if you’re seeing that with any payers that Evolent is their benefit management company.

So we do have struggles, and some of these you are having to do peer-to-peers, your physicians are, but there again, don’t give up the fight. Keep after it, because it’s vital at this point in time. We’ve made strides with this 412 since January, I feel like, and ASTRO is helping along with that. So we don’t want to go backwards from that standpoint.

 

 

This transcript was generated using AI. If you note any issues, please email us at secretary@sgrt.org. 

Catherine Sue Hwang, MD
Radiation Oncologist
AdventHealth Cancer Institute, USA

Transcript

Before we start talking about how SGRT is revolutionizing the field of radiation oncology, I just wanted to take you back in time to the early 2000s when I was a resident in radiation oncology. Back to the times when we were watching Tony Soprano, Carrie Bradshaw, and six friends hanging out in a coffee shop, and back to a time where Britney was still on the radio, and Justin was still in NSYNC. It was during this time that I was using a four-field box to treat prostate. I was putting wires on my breast cancer patients in fluoro to figure out what was the best tangent angle. We were matching photon and electron beams to treat head and neck cancer patients. And as the lowly resident, I was holding a plastic bag open for the therapist to pour foam into so that we could form these alpha cradles.

We were learning alongside with our attendings also at this time about a fancy new technology called IMRT, and this amazingly precise radiation technique allowed us, as you all know, to escalate dose while also sparing nearby normal tissue. And I still remember my very first pelvic IMRT patient. We simmed her on a Friday afternoon, and before my attending left for the weekend, she tasked me with contouring this patient. And she reminded me that it was really important that I do really good contouring because we didn’t want any of the high doses spilling out into the normal tissue. So I went in on a Saturday, sat in a dark room, and just literally contoured every loop of small bowel on every axial CT scan.

Come Monday morning, I was really excited to show my attending what I did. We sat by the treatment planning machine waiting for the plan to come up, and she asked me how long did it take me, and I said, “Oh, about four to five hours.” And she was kind of shocked and had no idea what I was doing for four to five hours. And then when the plan finally came up and she literally saw thousands of contours, she said that was interesting, told me a simple bowel bag would have sufficed, and then also introduced me to this amazing little tool called interpolation. I could hear the dosimetrist snicker as my face turned bright red.

Since my early days, I’m happy to say that my understanding of radiation oncology has come a long way, with a significant amount of my learning actually happening as an attending because of how quickly our technology and treatments are evolving. And while I must admit, sometimes I feel completely overwhelmed as you’re literally learning on the fly, it has been amazing to have this front row seat to all of this progress.

So we often talk about the war on cancer in terms of battles won and lost. But if we look at the landscape of where we are today, the map of that war has completely changed dramatically. And as early as 2025, we have an estimated 18.6 million cancer survivors in the United States alone. To put that into perspective, that is roughly one out of 18 Americans. And this number is projected to exceed 22 million by 2035. This figure is a testament to the fact that our treatments are working, and as more and more patients are walking through the fire and coming out on the other side, we must confront the reality of the aftermath, acknowledging the everlasting effects of side effects and treatment-related complications. For many patients, healing from the cure can be just as demanding as surviving the disease.

As clinicians, our primary focus has always been on prolonging quantity of life, with the patients themselves willing to undergo treatments that would eradicate disease at any cost. In training, I was taught that patients can live with treatment toxicity, but they cannot live with recurrence. So if push came to shove, you do not underdose the tumor. So back in the day of four-field box and matching photon electron beams, it was really common to find patients with significant treatment-related side effects. I still remember treating prostate cancer patients for five weeks, and then we would break them for two weeks because they could never make it through a nine-week course of radiation because of the unrelenting diarrhea and the proctitis. I also remember my head and neck patients who would come in with no teeth because they had such bad xerostomia that their teeth just decayed in their mouths, and they either had to be pulled or they just fell out. And I will never forget the left-sided breast cancer patient that reminded me a lot of myself, who I had developed a relationship with over my four years of residency, and at seven years, she didn’t show up, and it was because a few weeks earlier, she died of a heart attack. These patients are all examples of how clinical success means little if we neglect the long-term side effects and emotional recovery that follow a diagnosis.

Thankfully, over the years, our field has advanced to the point where what we do today is radically different than what we once did, and we are allowed to prolong quality of life without sacrificing quantity. Two years ago, I came to experience the impact of these advancements firsthand when a diagnosis of breast cancer transformed the disease from my profession to my personal reality. What should have been another routine Wednesday morning turned into one of the worst days of my life when I went in for a screening mammogram, which I get every year like clockwork. And honestly, I really expected to be in and out in 30 minutes because I was healthy, I had no risk factors, and I had no symptoms. So when they found calcifications in my right breast, I was surprised, but I wasn’t alarmed because honestly, calcifications like those mean early-stage disease, which is entirely treatable and highly curable.

And then I moved on to the ultrasound, and that’s when everything stopped. They found five masses in my breast, as well as an abnormal lymph node. And then the MRI just kept getting worse. They found small tumors pretty much in every quadrant of my breast, and I do believe the report read something along the lines of tumors that were too numerous to count. The biopsy of two of the biggest tumors and the lymph node were all positive for lobular cancer. As devastating as this all was for me, I kind of thought if I was going to get a cancer, I guess this would be the one to get. After all, I’m considered an expert in the field, I know all the treatment algorithms, all my close friends would be my doctors, and I could pretty much get any test performed within a matter of hours to days.

The first step of my treatment was going to be surgery. And because of how extensive the disease was in my breast, we could not do a lumpectomy. So I figured if I was going to get one off, we would just get both off, and then I got implants. Genomic testing showed that my cancer was low risk, meaning I didn’t need chemo. And as a radiation oncologist reviewing my own plan, I figured if I didn’t have any more lymph nodes, the size of my largest tumor didn’t meet criteria for post-mastectomy radiation. So I didn’t really think I needed radiation, and I just thought I’d go through surgery, be put on a pill, and then I would just kind of move on with life.

My cancer, unfortunately, had other plans. When I was taken to surgery, I had more extensive disease than initially anticipated and was deemed clinically high risk. Therefore, my oncologist recommended I get some chemotherapy. When I reviewed my own pathology, I saw that I had positive margins. I begged my surgeons to take me back to surgery because I did not want radiation. But unfortunately, there wasn’t much more tissue they could resect, nor did they have confidence that they could even find the positive margins. So unfortunately, this also bought me radiation. And to top it all off, a medication called Verzenio was added to my treatment because I was now high risk. And for those of you that don’t know, CDK 4/6 inhibitors can wreak havoc on your GI system. So it is certainly not an easy medication to tolerate. Suddenly, my simple two-step plan to beating cancer became a bit more complicated, and it was clear that there would be no quick recovery.

That being said, I healed well from surgery, and three weeks after the procedure, it didn’t look like anything had happened to me. Then I rolled into chemotherapy, and I was fortunate there too as well. Aside from extreme fatigue and the hair loss, I was able to work through treatment and be there for my kids. For me, the most challenging part was radiation. And I know it’s because I knew too much. Having spent the past 15 years of my life specializing in the treatment of breast cancer, I’ve seen every radiation complication. So radiation pneumonitis, broken ribs, chest wall syndrome, cardiac complications, malignant tumor induction. These were all the visuals that were floating around in my mind as I was getting ready to do radiation. I knew the risks were low, so I understand that. But when you go from being the one prescribing the beam to having to receive the beam, those percentages don’t feel low anymore. They feel like a looming threat where everything is a real possibility. Add to the fact that I am a type A self-diagnosed micromanager who feels comfortable when I’m in control, being on the table was a huge lesson in vulnerability and another reminder of how I wasn’t in control, the cancer was.

I chose to be treated at my center with my therapist that I’d spent years working alongside of. I realized there could be a certain level of awkwardness as I had to lay topless on the table. But I also realized that we were all professionals, and for the 15 minutes I was in the treatment room, I would be the patient, and they would be the therapist. My partner was my treating physician, and she prescribed 16 fractions. Because my chest wall shape is more rectangular rather than oval, we had to use IMRT because 3D just resulted in too much lung in the radiation field. We also utilized deep inspiration breath hold, which at our center is standard regardless of what side the cancer is on. At the time I was undergoing treatment, we were predominantly using RPM for respiratory monitoring. While we did have SGRT, not all the therapists were trained on it. It kind of slowed us down because we weren’t quite sure how to fit it into our workflow, and we really just reserved it for special situations. So it wasn’t considered standard at the time.

RPM, as you all know, is respiratory motion technology that uses infrared cameras and a marker box placed on the patient’s abdomen to track chest wall motion. So RPM is monitoring a surrogate, not the actual target. And in my case, it didn’t work. My abdominal breathing was surprisingly inconsistent, and I was unable to maintain my breath hold in the specified range. While I thought I was breathing like a champ, RPM did not. So that’s a normal one, and that’s what you want, and that was literally me. It just shot straight down. So as I lay on the table waiting for the sim to be over, my therapists were literally drawing straws to see who would come in and tell me the bad news. And they knew I wouldn’t believe them, so they actually took a picture of my waveform and showed it to me as I laid on the table with my arms above my head in the back lock.

I knew what this meant. Under the RPM standard, I would’ve been deemed a failure and treated in free breathing. This was personally devastating, and I was already struggling with the idea of radiation, and now without the ability to do breath hold, I visualized radiation just shooting through a lot of normal lung, my liver, and a little bit of my heart. This is where the power of SGRT became undeniable. My physicist suggested that we use AlignRT to see whether my abdominal movement was the issue or whether my breathing just truly was bad. And do I just hit the button? The instant that we looked at the actual surface being treated, we found I am an excellent breath holder. So by tracking thousands of points across my entire surface, it wasn’t guessing, it was seeing. It accounted for my six degrees of freedom, which RPM does not, and it gave me the submillimeter peace of mind I needed to relinquish control and finally be okay with radiation.

It took me being the patient to realize that SGRT doesn’t just manage motion, it manages human variability. This realization was humbling and quietly transformative because for me, this was the first time I understood that the true value of SGRT wasn’t technical superiority alone, but it’s respect for the reality that patients are not rigid objects, and that the safety and trust emerge when technology adapts to the person, not the other way around. And yet technical precision is only meaningful if it serves what comes after treatment. As our tools become more exact and less destructive, we don’t just control disease, we protect the possibility of survivorship where healing continues long after the last fraction is delivered.

Many people who have never been patients see the cancer journey completing once treatment is done. But what many survivors know and what I know now, is that survivorship is a long winding road that lasts the rest of the patient’s life. It tends to be the most challenging phase of all, despite traditionally receiving the least amount of medical attention. As we push past 18 million survivors in this country, we must continue our commitment to precision care because quality of life needs to be valued just as much as quantity of life. And technological advances are the key for allowing us to do so, as advances allow us to be as precise as possible, buying the patient and the treating team peace of mind.

While in the beginning, SGRT may seem like extra work, it is actually a workflow optimizer providing the therapist with an objective go, no-go signal and removing the subjectivity of looking at a marker or interpreting a waveform. By implementing SGRT, you are building a system that is self-correcting. You are reducing the need for repeat imaging and redos that kill a machine’s schedule, as well as the patient’s trust in the therapist. You aren’t just buying a camera, you are buying time and certainty. And as a patient, I know firsthand how certainty is able to replace anxiety with confidence.

We’ve come a long way since my residency, thanks to systems like Vision RT, which provide the essential technical foundation to push the treatment envelope and redefine successful outcomes. When we invest in this level of certainty, we move beyond simply delivering radiation to providing a higher standard of compassionate, precise care. Ultimately, as our technology advances, our patients’ peace of mind and quality of life can finally advance alongside of it. Thank you.

 

 

This transcript was generated using AI. If you note any issues, please email us at secretary@sgrt.org. 

David J. Gladstone, Sc.D., DABMP, FAAPM
Professor of Medicine and Engineering
Dartmouth College and Dartmouth Health, USA

Transcript

So I’ll be speaking on clinical treatment and process quality improvement due to Cherenkov imaging. And I thought I’d lighten it up a little bit by quoting Hank Williams Sr., who wrote “I Saw the Light,” and it was released in 1948. Seventy-seven years later, a very little-known physicist wrote another verse to that tune, and this is the world premiere of that verse. So it’s:

“I saw the light, Cherenkov light. There’s no more questions if the beam’s too wide or tight. We’re all so happy when we treat our patients right. So praise the Lord, I saw the light.”

Well, thank you. You’re too kind. So, this is my band and a couple of important people here. If you’re looking at clinical implementation, you want to speak with Rory Rosselot at Dose Optics. She’s probably seen more Cherenkov images than anyone on the Earth and really is an expert on practical implementation, getting things going.

The next most important people are the graduate students. And I just heard this last talk by Josh. It was awesome, about beam sight or beam guide—I forget already what we call it. And so the question is, why would you need to look at the Cherenkov images at all? And the answer is my newest student, Bomi Lee. She’s a sophomore right now. And we’re working on a method to get actual dose from the patient, which has always been a confounding factor because of tissue optical properties, including blood content, melanin content, and that sort of thing. But we think we’ve got our hands wrapped around that right now.

So, I’ll get to physics now. Cherenkov light is part of the megavoltage radiation dose. When X-rays or electrons are impinging on tissue at faster than the speed of light, they polarize that tissue and the depolarization event results in emission of visible light. So here’s a nice example from nuclear fusion in a fuel cell. You see the nice blue glow. For those of you who may have caught me breaking a law of nature or physics, no, I didn’t. $3 \times 10^8$ meters per second is a limit in a vacuum, but we’re in tissue or medium, and so light obviously is scattering and going slower in that tissue. Electrons, however, can still go faster than that speed of light in the tissue.

Monte Carlo calculations show us that the Cherenkov emission should be absolutely proportional to dose. As I’ve already mentioned, people get in the way of everything good and pure, and so tissue optical properties keep us from having a linear response. However, we can irradiate a phantom, and this is a phantom. It’ll show back up at the end of the talk. Rongxiao Zhang put that together. He was the first graduate student to observe Cherenkov emission from a clinical beam in a water tank, and he put this cute little phantom together.

So you all know that the trick is done with cameras in addition to the Vision RT cameras mounted on the ceiling. The actual trick is that our linear accelerators are delivering irradiation in pulses, right? So we’ve got these three or four microsecond pulses that are spaced every ten milliseconds apart. And what we do is use this pulse of irradiation to trigger the image intensifier on the camera, so it’s only acquiring data when there’s actual data to be acquired.

So an example of a live image, you see the beam changing shape. You also see superficial vasculature in that first frame, and maybe it’ll pop up again. But that vasculature can be used to fingerprint a patient, if you will, but it’s also indicative of these tissue optical properties that can get in our way of thinking just about dose proper. Cameras are mounted on the ceiling. These are two of our vaults. You’ll notice probably some extra pods up there because we’ve done some research as well.

Another part of the trick, as you know, is that there’s structured light which is projected by the Vision RT pods, and that same signal that’s used to trigger the image intensifier is also used to mute the projector out of the pods so that we don’t have light interfering with the process. This is just an indication of a patient being treated, and you can see in real time that the field size will change with beam modulation. And at the end, we get this summated image where the bright yellow is higher dose levels and the blue on the outside is lower dose out at the beam penumbra. Here you can clearly see that tissue vasculature as well as a perceived intensity change due to the areola nipple complex.

This is a cute observation that we made. On the left is the cumulative view building up, and on the right is the real-time image. This is a stereotactic radiotherapy for a posterior orbital tumor, and what we see there is light being emitted from the patient’s lens due to transmission through the vitreous humor. So everything was proper. The location of the tumor, as you see in the lower right inset, mandated that we have some dose to the posterior orbit. But the surprise was it was actually shining out of the patient’s eye.

So four key areas where we can see improvement in radiotherapy are patient setup, treatment planning, use of accessories, and patient compliance during treatment. So we had this prospective study of the first 60 patients that Josh referenced, and first case out of the box, and what do we see but chin dose. So, we can move the patient’s chin out of the way or think about replanning the case. Case two was limb monitoring, so we’ve got a little bit of spill going off to the contralateral leg. And one can use the frog leg position for a single leg if that would be a little wiser than just letting it go.

We’ve got these setup and planning real-time discovery of issues. So here we’ve got chin dose before adjustment, and then moving the head out of the way, we can avoid that. And this turns out that it was already in the treatment plan from the beginning, but it wasn’t noticed either by the dosimetrist, the physicist, or the physicians, because people are not in the habit of turning the dose cloud down to the 10% line, right? We’re always focused on what is the treatment dose. Are we covering the tumor? But we’ve got these low-dose areas that can be important as well.

Another case study is bolus alignment. So in the upper panel, that’s a properly aligned piece of bolus, and in the lower panel, it’s too far posterior and we’re missing the medial edge. Another case where the dosimetrist was hand-adjusting the multileaf collimators and left the inferior-most set of collimators in the open position, and it created a stripe on the patient. This, again, was missed through all the treatment plan review and was picked up only during the treatment. Here’s another case of bolus misplacement. You can see light piping to the edge of the bolus, and so it becomes immediately obvious, and I just won’t belabor that.

Here we have patient compliance. They’re supposed to be holding their hand up but drops it during the beam delivery. This is an exit field from a pelvic spine treatment. Probably not much harm done with that exit dose, but nonetheless, it’s not best form. So may as well come up with a better plan of immobilizing the patient.

This is the first patient treated at a site where DoseRT was installed, and the first thing we saw was dose to the contralateral breast, and that was unexpected. Yeah, just the 3D rendering of the same thing. So, this contralateral breast dose turns out to be quite more common than we had imagined, and so we opened a trial internal to Dartmouth called the EDUCATE Trial, evaluating dose using Cherenkov and scintillation technology. This piggybacks on a WE CARE study, which was done a number of years ago by another institution. They found that dose in excess of one gray in young patients results in excess contralateral breast cancers. So this is actually a clinical finding where you want to keep the dose low in order to avoid long-term morbidity, which you probably wouldn’t expect from such a low dose.

Since that’s been published, we’ve seen a lot of changes in techniques, and so especially with the adoption of VMAT technology, and accelerated partial breast irradiation, inclusion of intramammary nodes, one can imagine that there is indeed more spill of dose to the contralateral side. So we went into this thinking that perhaps the incidence of contralateral breast dose is underappreciated.

So in the objectives—Gosh, I stole somebody’s slide, and I don’t know what the animation does, right? So the objectives were to establish what are the incidence of contralateral breast dose in our routine clinical practice. We want to quantify what that dose is using Cherenkov image-guided in vivo dosimetry. So it’s nice to think that you’re going to put a TSLD or a OSLD or a TLD on a patient surface to measure the dose at a spot of interest, but how do you know where you’re interested? So the best way to do that, we think, is using image guidance from the Cherenkov images. And then lastly, we want to determine the root cause of that contralateral breast dose. We need to distinguish between that which was planned and unplanned, and we’d like to come up with techniques that minimize that dose in the future.

So, we ran the Cherenkov imaging on all of our patients at both the core academic medical center as well as one of our community hospitals and measured contralateral breast dose when it was detected. So we imaged 129 unique patients over 1,800 fractions, reviewed those for over six months, and found that 94 of those patients were treated with supine technique. Not surprising, the majority. Contralateral breast dose was identified during delivery in 43% of those patients, and that is a surprising result that it’s that high.

The spread of these observations were that normal tangent treatments, not so bad, six out of 56. Wide tangents, 93% of those cases had contralateral breast dose included, and of course, that’s to get the IMNs when you just open up your tangent fields. Tangents with medial electrons mixed in, two of two. Not strong statistics, but yet we expect beam spread and wide penumbra from an electron beam. And then accelerated partial breast irradiation using VMAT, 100% of the cases had some kind of contralateral breast dose detected.

So it was unplanned in about 10% of the cases. These are cases where planned and unplanned, just two different examples. And a combination of planned and unplanned also occurred, so the patient on the right-hand side. And here you see the marker block that people have talked about today. It’s pretty easy to understand that. I heard a lot of questions about it, but I tried it on myself. So if you lie on the table with the block on your abdomen, you cannot breathe at all and make your abdomen go up and down, right? So belly breathers, chest breathers, people who play trumpet like to breathe from their belly, right? You need a big volume of air. So that’s not a really robust way of tracking breathing motion. Although here you see it moved up superior on the sternum, so it could do a little better job of monitoring the chest wall.

Dosimetric measurements from the three different sort of techniques, so wide tangents, tangents plus electrons, and accelerated partial breast irradiation. The TLDs were showing anywhere between, well, negligible and two gray, actually, in one fraction. And so if you add this up, the contralateral breast dose can vary between negligible in the case of the VMAT and up as high as 40 to 48 gray. If that were to occur in a younger patient, you can be almost assured that it’s going to result in a long-term toxicity. The limits that we talked about were to keep that dose low, and patients under 50 did have contralateral breast dose in excess of our constraint of one or two gray. So future work is going to be monitoring every young patient with the Cherenkov imaging and try to reduce that to zero so that we don’t see those long-term adverse events. So this, again, the animation, 17% of those younger than 50 had these issues.

So to recap, we’ve got suboptimal planning where dose can be originally planned to be hitting the contralateral side but underappreciated. We’ve seen patient motion during treatments, which we pick up with the imaging, and inconsistent bolus placement.

So in summary, we can see real-time delivery of the dose. It’s recorded so that the teams can look at it retrospectively. Images do show daily variations. Non-ideal delivery can result due to these four features that we’ve already talked about. And Dose RT, I claim integrates seamlessly with SGRT, but we should really hear from end users. The therapists at our center actually love it. We’ve installed it now in every bunker across four facilities at Dartmouth. They actually like the Cherenkov imaging monitors better than the CCTV cameras because the images are crisper, clearer, and you get the extra information. So if you want to declutter the machine, it’s my suggestion that you get rid of the normal CCTV, replace it with Dose RT.

Once in a while you can get shown the light. In the strangest of places if you look at it right. Yeah, an actual band.

 

 

*This transcript has been AI-generated. Contact us at secretary@sgrt.org if there are any issues.

Guy Jones, MD
Radiation Oncologist and Medical Director
Oncology Nevada, USA

Transcript

My name is Guy Jones. I’m a radiation oncologist and medical director for Oncology Nevada in Reno. I also have some clinics in several other states, including elsewhere in Nevada, in Las Vegas. It would seem like a different state, but it’s not, and Washington State, Alaska, et cetera. I want to talk about the clinical value of SGRT’s use in radiation therapy across all body sites. We are heavily pelvic, prostate specifically, but we treat all kinds of cancers and benign conditions in our clinics, and so this is used across the spectrum.

A little bit about Oncology Nevada: we are a freestanding physician-owned clinic in Reno. We have a very high-volume center where we treat anywhere between mid-60s to mid-80s on a single Varian TrueBeam, and about 70% of our cases are prostate. We have block times, they vary, but around 10 minutes. The way I got originally interested in Vision RT was when I was practicing in Washington State in the eastern side of the state. Anybody know the Tri-Cities? That’s where I’m from, that’s where I grew up, and that was my first job when I came out of training, and I was really interested in doing treatments for trigeminal neuralgia, like stereotactic ablation procedures. We had a Varian Edge at the time, and we could use a virtual cone to treat, in theory, but really it hadn’t been justified to treat trigems using a non-invasive system and with just surface guidance. So I started that program in the Tri-Cities about maybe eight years ago and treated about 100 trigems over a couple of years there. So I was really kind of surprised how much volume we had. And then we wrote up our paper for a stereotactic conference, and we were giving 90 gray in a single shot to that nerve root of the trigeminal nerve just right next to the brain stem using SGRT. And it worked. We had really essentially no toxicity and good outcomes comparable to anything else out there, CyberKnife, Gamma Knife, et cetera. So it got me really interested and confident in the technology, and so when I came to Reno, I not only deployed this at our site in Reno, but also across our other centers that I either own or am affiliated with.

There’s a lot of benefits to SGRT, and I’ll go through them in no particular order. But I’d say one of the big ones is just being able to get away from tattoos and having just markerless treatments. So it seemed like a small thing. Actually, patients do value it a lot more than you would think they do. And there’s a lot of reasons for that. There’s psychological reasons, et cetera, but it is also more accurate to not line up just on small little points, but to do it over a stretch of the body. And that’s essentially what SGRT allows you to do, specifically the Vision RT system.

So what we have found—well, not just us, but in the papers—they’ve shown that it reduces the shifts that are done. It also reduces the treatment time, and it reduces the amount of additional imaging you have to do. So, when you do your initial IGRT, you do the setup, you just don’t have to reshoot the images that often. In fact, it’s about a two-thirds decrease in the amount of re-imaging you have to do, which is something we always document, and it isn’t considered necessarily a medical event, but it’s something we keep track of, and it is important to reduce patient radiation exposure. It’s just that general ALARA principle we all talk about.

I love the way the interface is on this. And one thing I want to just back up a little bit and say is that our center, you can imagine, if we’re treating 60 to 80 patients a day on a single machine, and our manager, supervisor, therapist is in the room, the first thing they brought to me and asked, and the first thing I asked this company was, “Can we ensure that this is not going to increase our treatment times? Because we cannot reduce throughput.” You add a minute a day, you’re there for another hour and a half. You can’t do it. So it needs to be at least neutral, if not a time savings. And we put it in, and we’ve seen exactly that, which is exciting, and that’s been true across our centers. One of the things I found kind of interesting is that they removed SGRT as a reimbursable part of SBRT treatment, and yet when I gave the option to my therapist saying, “Well, we’re not going to get paid for this, so you don’t necessarily have to do it for SBRT,” they said, “No, we’re going to keep using it because we like it and it helps us set up better.” So it was kind of proof of principle. At first, it was like having to pull teeth to get them to do it, and then once they started doing it, it was like, hey, I can’t really take it away from them. So I think that shows a lot.

So a couple of different things. You guys all know this. This is maybe not the best audience for these messages, but this is for intrafraction motion management as opposed to interfraction motion management. This isn’t setup. And that needs to be clearly documented in your medical necessity so that we’re not talking about just another IGRT. If it worked the same as IGRT, you’d just use IGRT, or you’d just use this, one or the other. But it’s two different things. One is what you’re setting up to initially, and then after that you’re going to… Are you guys hearing feedback, by the way? This is throwing me off a little bit.

Yeah. All right. I don’t really know what to do about that. Maybe step back a little bit or move up. That’s better, isn’t it? Sorry. You want me to start over? So, this is actually relevant across disease sites. So not only do we have it for prostate and pelvic… I’m still getting the feedback. Is everybody still… There’s something wrong with the electrical in this room. All right. Is it tolerable? Can we just go on with it? Okay. All right. I’ll just do that. So again, we treat a ton of prostate, we treat a ton of pelvic aside from that. We’re treating pelvic lymph nodes, and then especially for abdominal targets, frankly, I would not be comfortable without some strict motion management if I was treating SBRT pancreas. I need that for something like that. So, there are certain things where it’s just an absolute must, and it’s most important, ironically, for SBRT, which is where this code got pulled out as a separate billing code. Which is counterintuitive, but why does CMS do half what it does?

One thing to keep in mind is that we’re not—and a lot of people have talked about this—it’s like a thin line between, okay, we’re not really monitoring the tumor, we’re monitoring the surface of the body. Those are two different things. Well, it is and it isn’t. It’s a surrogate. It’s no different than when we used to set up just on the skin and then maybe had some crude imaging, old MV films, for instance, and you couldn’t see hardly anything, and you’re kind of hallucinating it. But you’re still tracking. You’re setting it up based on external anatomy. So, it’s essentially the idea that external anatomy does correlate with internal anatomy, which is common sense, but at the same time, it’s something that’s been brought up as maybe two distinct things. They are essentially one and the same. When you monitor the body, you are using that as a surrogate for the internal anatomy, and that’s the reason this works. Along with tattoo-less delivery, the reduction in the treatment times, fewer shifts, less repeat cone beams, things like that.

So again, it’s not just for positioning, it’s continuous intrafraction motion that is really what makes this important and makes you be able to give a clinical case for the billing case, which unfortunately is a reality that we all face. Again, sub-millimeter accuracy. We have reduced setup errors and less re-imaging, real-time motion tracking without immobilization, faster setup, and then the tattoo-less options. And all these things have been clinically documented. These are all peer-reviewed PubMed articles that are in my clinical justification document that I put in for every patient that we’re doing SGRT on.

The final rule that came out—well, it’s not a rule anymore. I guess this is an older slide. It is the final rule, but it’s now the current rule. This 77412, as many times as we can capture that, the better. Obviously, we all took a hit this year. This was a big mess. It’s still a big mess, and we’re sorting it out. But I would say that it definitely, in terms of Medicare CMS, that very much the SGRT fits what the spirit of this idea of why we should be able to justify 77412. But we found even most of the commercial payers, aside from a couple of problem children, the normal ones, United and Blue Cross, they are paying it. And I think we’re capturing over 90% 412 in a couple of our markets, but not all of them. So your market may vary.

The key to reimbursement on this, though, is to have any chance of it and frankly, to reduce the chance of an audit or anything like that, is you do need the clear documentation of SGRT use. And then you also need the justification through a letter of medical necessity that we upload, and that’s how we’ve been doing it for several years now. I should say, we’ve had Vision RT for maybe three years or so now. So it’s been a while, and we’re really glad we did it back then because we could get paid for it. Now, we’re just glad we have it so we’re not reduced in our current reimbursement because we’re getting so much 412.

So the things I put in my letter of medical necessity, my documentation of medical necessity, are that it’s utilized again for intrafraction motion. So again, to separate it from IGRT, that surface tracking is being used as a surrogate for internal target positioning. And I do say things like, if somebody coughs, fidgets, or any otherwise adjusts, these are things that you want to just have that in there spelled out as some reasons we would want to use this. That there is beam held. The automatically part, that’s going to be interesting whether there’s any clarification on whether it has to be automatically held or whether you can just set a tolerance and watch it. Right now, it doesn’t seem to matter, and based on some discussions with some of the higher-ups in ASTRO leadership, they didn’t think that it necessarily needed to be automatically integrated. And so except for one of our sites, we haven’t really been doing that. But just something to say, “Hey, the tolerance should be X amount.” Document that in your letter and in the simulation setup note, and then you should be good to go. And then you want to say that it’s required to maintain treatment accuracy and reduce the dose to OARs. That’s the whole point to this, is that you’re hitting the right spots and not hitting the things that don’t need to be hit. And then it allows reduction of PTV margin along that same idea.

For daily treatment documentation, this one’s nice because it’s essentially been done for us. Vision RT has an integration with ARIA, and it shows up in your offline review checks. So same place the IGRT images are popping up, there’s a form that’s automatically showing that we used SGRT that day. So it’s just one extra click of a button for each patient every day. It takes no time at all. So this was nice in that before the therapists were having to upload each individual one, fill out a form for each individual one, now it’s all just done automatically. So if you do get this system, I highly recommend you get the ARIA integration. And I don’t know if it’s available for the other—Is it like Mosaic too and others? I don’t even know. But it is? Okay, I’m getting a nod, so I think it is available for the others.

So the billing pitfalls, the things you absolutely need to make sure are not in your documentation are that you aren’t using the SGRT just for setup. In fact, we say not just for setup, using for intrafraction motion. Make sure that sentence is in there. You want to say that you’re beam-on monitoring. Again, a lot of that’s done for us through the ARIA integration, but it’s still just make sure it’s in your letter of medical necessity. You want to say some defined tolerances. Everybody’s going to say something different. You want to have, again, the statement of medical necessity uploaded alongside your clinical treatment plan and then, again, have it in ARIA somewhere permanently in case you ever get come back and get audited.

So again, the ARIA integration we talked about has made this really, really easy. You can see it’s just right up in the offline review on the bottom. It’s just one extra thing. Instead of an image, it pops up a document, just sign it. And this records all those things we were just talking about that need to be recorded.

Couple of things when you first integrate it, and like I said I did, whenever I bring something forward, and the therapists are really busy at our center. Most centers I know of, they’re really busy, and so these are things you’re going to have to… What we did is we just kind of found a champion therapist amongst the group and just said, “Hey, are you interested in this technology?” And she said, “Yeah, this sounds great.” And we just said, “Will you help us roll this out?” And she became kind of like a lead of this technology, and she’s been to a couple of the conferences and had a great time. But this is going to require some buy-in from the therapists, and you have to just let them know at first this is going to be a little frustrating, but then pretty quickly you’re going to get used to it. And I will offer our sites if there is any of your therapists that want to come take a look at how this is used in a high-volume center. I know Laura’s happy to have them at Reno. We’re happy to have them down in Vegas or any of our other sites if that would be something that would be helpful. Just let me know.

So the system QA does require some calibration. There’s some initial setup learning curve as there is with any technology. And then you need to make sure that integration and the ARIA documentation is going through, so there’s just an extra paperwork step that they need to at least make sure is in there. Fortunately, they don’t have to upload it manually like they used to. But again, it’s decreased treatment times across our center, which ultimately is something that they’ve valued, being able to get out a little bit earlier than before. And also we know we’re doing a little bit better for the patients as well.

So in conclusion, this is an active motion management system. It’s clinically validated, widely adopted, a lot of PubMed studies on it. Not just this technology, but a lot, but they’re all pretty similar. Supports precision, safety, and efficiency. Over 300 studies growing adoption. It used to be, I forget what, I think it was first used in the brain, and then over the next five or 10 years, it’s been now considered medically necessary for all body sites, including pelvis, and that’s in the peer-reviewed literature. And it gives us not only time savings but supply savings, staff savings, and then allows us to increase our throughput and provide a better quality of life for our patients and our staff. So really happy. I think this has been a big success story for our clinics.

 

 

This transcript was generated using AI. If you note any issues, please email us at secretary@sgrt.org. 

Mike Tallhamer, DABR
Chief of Medical Physics
AdventHealth Parker, USA

Transcript

So we’ll talk about the future of SGRT. I don’t know, so don’t hold me to anything I’m about to say. It’s all going to be speculation. We’ll talk about what’s happening right now in SGRT. We’ve talked about a lot of new products that are coming into the market in this field or in this area, and we’ll talk about these things from a clinical perspective, but also from a perspective of automation, integration of care, and how these things can better be utilized within the clinic. And then we’ll do some speculations and look at some pet projects that we’ve done at our facilities out in Colorado. Some labors of love from one of my physicians as well that has some implications within SGRT, and we’ll just go through that. And hopefully it just sparks some ideas in your mind to take back and have conversations with your staffs, and about how you could be using SGRT potentially in different ways within your clinic.

So again, my disclosures haven’t changed since about an hour ago, but if you want to drop bags of money on me after this, I will add you to this slide with no problem. But when they ask me to talk about the future of SGRT, one, I’m always like, “Huh, what does that mean?” But we’re going to talk about why this conversation, why now. We see a lot of innovation in this field as we’re talking about all these new exciting projects, as we were talking just now about the Cherenkov imaging, about two speakers ago, talking about how much he loves Cherenkov imaging. I am super jazzed about Cherenkov imaging; it’s super cool. If you come out to the site visits this afternoon, we’ll be showing some examples of that and what it looks like clinically on phantoms. Obviously not on people, so don’t worry, we’re not going to radiate anybody when you show up, so you’re going to be totally safe.

But I spend countless hours playing with Cherenkov imaging and trying to find ways that it’s going to be more and more applicable within our clinical setting. In fact, my wife thinks I’m dating a girl named Cherenkov right now and wants to know why she’s ruining such a happy home, because I’m never there. But it’s an addictive tool to play with because there’s so many things that we don’t see in the clinic. So why this conversation, why now? We all know that patient volumes are increasing, at least across our centers right now. Patient volumes are increasing, but staffing capacities tend to stay relatively flat until there’s significant justification. And we need additional throughput, but we don’t want to sacrifice accuracy or that touch that we heard people talk about earlier with our patients and that connection with the patients. And so SGRT is positioned to bridge that gap for everybody.

There’s technology convergences that are happening now within radiation oncology. I’m seeing more and more adaptive planning being introduced in community settings, so like community hospitals putting in Ethos, which a couple of years ago were a university style thing, which needed a lot of additional staffing and a lot of additional time at the machine, and now we’re seeing these things pop up in community cancer centers. Those things are dragging with them AI. We’re using AI for contouring, AI for evaluation of imaging, AI for all the different types of things. I know Anton and I are always talking about AI and where he’s ready to embrace his computer overlords in the future, and all the robots that are going to take over all of our jobs. I don’t think that’s going to be the case, but AI is going to be a tool that we’re going to be using in the clinic and how can we roll these things into these platforms. Protons with their new small form factor, protons that are going in standard vaults are now becoming more attractive and cheaper. And so I’ve even heard community cancer centers are looking at putting in single vault proton facilities, and making a hard go at going bankrupt. And so all of those things are out there. Sorry if there’s any proton vendors in here, I really apologize. They’re super cool too, but I don’t have one.

And then we have tattoo-free types of treatments, maskless head and necks, which I know Dee gave a talk on yesterday, and things that we’re doing as well out in Colorado in AdventHealth. These things are all patient satisfaction type of things that we’re going to provide to our patients as a measure of things they’re going to begin to expect in the future as these become more prevalent as well. So how many times if someone walked in and said, “Do you do protons here?” I anticipate in the future how many people are going to come and say, “Do I really have to wear a mask? I can go across the street and not have to wear the mask.” And so SGRT is fundamentally positioned to address all of these things in the future, and I think that it will in successful ways.

And so we’re going to talk maybe three stages, three parts to this talk, about what’s going on right now. And what’s going on right now, if you come to AdventHealth, this is later on this afternoon, we’ll talk about these workflows, sim, plan, treat, dose. We’ve heard this over and over and over. And there’s products within these spaces. So we have SimRT, MapRT in planning, AlignRT in treatment or AlignRT inborn treatment, and the Cherenkov imaging system called DoseRT at treatment as well, but visualizing dose instead of surface positional information. These are all great products. These are all things that are out there, and we’re all very excited about these things, but they are individualized products right now and things that we integrate within a workflow.

We have four established pillars of clinical use. We all know that SGRT is fantastic for initial setups. We hear about all, I think every other day, there’s some LinkedIn post where someone’s getting some glass trophy for going tattoo-less. The active motion management, we’ve heard about all of the active motion management, the drive towards that with the 2026 billing changes. But this has been a motion management tool for many, many years. I’ve been doing this for 15, 16 years at this point. And it has just always been an active motion management tool. We all know, at least from the published evidence, probably the most evidenced application of SGRT for deep inspiration breath hold and respiratory breath control. We know that it is well established. There’s tons of documentation for that, as well as the precision and accuracy of these SGRT systems for SRS and SBRT. But the nice thing about SGRT is that it’s for every single patient. So if I commission a system as a physicist for SRS, I get that SRS precision on every single patient. I don’t dust off a special set of immobilization gear to treat a patient anymore. I am giving every single patient the same SRS precision, regardless of who’s there, what they’re being treated for, or why they’re under my beam. They all get the same thing, which is a powerful tool that spans that huge patient population.

There’s new applications. So what’s going on right now is we’re seeing an explosion of invention. So we have surface-based planning. This surface-based planning is well evidenced as well. If you look at the literature, this table, I just gave an RSS talk about non-coplanar planning and looking at just publications since 2020, we see things for GBMs and for brain metastases and SRS. We see it for hippocampal sparing whole brain, head, neck, cervical, GYN cases, liver and lung SBRT, prostate, all of these things, and whether or not they’re evidenced, what is the advantage? So scale, I use check marks, you can use whatever you like, but the more check marks, the more advantage that these papers have said that non-coplanar planning brings to these types of cases. These are the references I’ll give you on the next slide in case you get this after the meeting, so you can look them up if you want. And the disadvantages are largely around the complexity of the workflow. So how we plan these people, how do we go through a workflow? We have non-coplanar treatments, and we have to worry about additional collision checks, those types of things. All of these things are being addressed by an SGRT product. And so we can, with high fidelity, set these patients up into the position that they were simmed at, and then we can predict now with MapRT whether they’re going to have a collision issue at the time of treatment. And so we can incorporate this information into our planning so that the complexity argument kind of goes away. It’s not that complex. They’re telling you the answer at the time of planning. You just have to have the faith in the tools and the understanding of how to apply the tools.

And so these are just the references from the previous page. So this is largely if you just get this afterwards. We talked about this in scripting, so if you weren’t in here, the power of surface-based planning is the fact that I can take a CT. This is the standard CT. This is all I need for dose calculation. This is what I can get with optical surface guidance, and then I can get a fusion of these information down here because everything I’m worried about colliding with in non-coplanar planning exists outside of the CT. And so if you weren’t in that talk, we showed an example of using the tools appropriately. So we have a CT, we have an optical surface, we have a fusion, and we can see that these tools can be used incorrectly as well. So there is a need for robust QA programs, an understanding of what is a procedural issue and what is an actual technical issue. If this was to happen, we cannot trust the clearance map, but we can actually use an incorrect clearance map if we don’t understand these things to put a patient in harm’s way, and we don’t want to go that direction as well.

So there’s this tool, again, something that we’re playing with. This is a caching mechanism for caching these clearance maps so that we can hunt for isocenters. So we saw a great talk on lattice or spatially fractionated treatment with these large tumors and showing the challenges that we have with clearance. But if we can actually have a tool that now optimizes the solution space and allows us to virtually hunt within the clearance space in 3D, we can actually find preferential things where this case specifically, I can actually extend this arc all the way around the patient if I just choose a better isocenter location. And so we can start using these tools in the future to actually help us to better integrate the tools that we already have, but also make our plans more effective and much quicker to implement, even though they are complicated as we would call them right now.

There’s the dose visualization. Again, my girlfriend, Cherenkov, my favorite person to hang out with in the evenings. And then now we have BeamGuide. So now we can now project into the future. As we’re sitting there setting up our patients, we can see or have that knowledge of what was intended from our physician and what was approved and what we’re looking at right now. Is that going to be executed? We don’t have to wait until after execution and then kind of triage what happened or what went wrong to make changes for tomorrow. We can make changes right now so that we can prevent the error right now. And what that looks like, this is one of my favorite cases that we’ve had at our site. This is a prone breast, and this was delivered for two days, and we see what it looked like for the first two days on the left. And then on the third fraction, we had this, and this was a kind of an aha moment for us with DoseRT of the power of what this was doing. This young lady had a bad back, had issues with her lower back, had pain, and so she was trying to bear her weight on her elbows. So instead of being really stretched out the way we wanted her to, the way she did the first two days, she was pulling her elbows in to kind of help hunch her shoulders and bear her weight on her arms rather than across her back. And in seeing this, we were able to address her pain issue and stretch her back out, and we were able to identify this very quickly. But that introduced a question of, well, could we have avoided that? Would we have known that when we set her up? Because we set her up with an ROI across her back and everything looked great. Her breast looked great. We just didn’t have an ROI on her arm. So how would we have caught that? Because the postural video kind of gave us that this was going to be okay.

But if we look at that same scenario, what happens if we see these things on day one? So this is an example that Anton gave. This is a prone breast from here in Celebration. This is also a prone breast from here in Celebration. And how do we know that these are the planned exposures? If this is our first day, we don’t have previous days of references to go off of assuming that those days went well and this day is maybe not going well. Well, if this is the first day, we can look at this and say, well, maybe she’s rolled into the hole too far. Maybe she’s rolled away from the hole too far, and these could be an underexposure and overexposure, but we have to have some sort of a priori knowledge of that plan. And we do our plan checks, and we do those things, but these are not traditional things that we’re rolling into our workflows. But now with BeamGuide, as we’re setting up the patient, we are getting the intention that was approved by the physician and seeing that, yes, in fact, this is the intended exposure for this patient for whatever clinical reason, and this is the exposure for this patient, and then the actual delivery conform to that exposure. So we’re now seeing as we have invention, we also have synergy between these tools moving into the future that we can use these tools in conjunction with one another to get answers ahead of time and apply a cheat code while we’re setting up our patients.

And then we have the AI, the advanced workflows. We have advanced workflow integration into OIS. We have the OIS module. We’ve heard a lot of talk about that, where we’re now promoting SGRT into its full capability or its full adoption into the image guidance space, rolling that into the OIS like we would any of our IGRT workflows. But we also have adaptive workflows and proton workflows and those types of things that we have to look at. So we have to look at what’s changing in this space as well. And so for those of you who do adaptive, please don’t judge me. This is the most cartoon adaptive workflow I could come up with. This is adaptive workflow, and right now you have some sort of daily imaging plan of the day. You go in, you look, this doesn’t look right. You’re going to maybe do an adaptation. You’re doing this on-table adaptive approach. You may make the decision to replan. And now the SGRT is basically a reference, and we’re watching our patients while we’re doing 30 minutes worth of work of transferring contours and those types of things. We can take this and shift this mentality of saying, “Okay, we’re going to treat yesterday’s plan. We’re going to set up to yesterday’s plan, and we’re going to do all the on-table adaptive stuff and make these decisions.” But as we move these things into high-volume community cancer centers, this might not be the way to go. We might need to set up to today’s plan with today’s surface and have different today’s tolerances. Maybe the internal targets are in a different orientation, or there’s different filling of different organs, and we might want to have tighter tolerances today. So we have to start thinking, well, how does SGRT play a role other than just eyes in the sky, they’re not moving while I’m doing adaptation, to something maybe in the future where we have a pre-treatment, maybe pre-table adaptation. So I can think of ways to use SGRT all the time. It would be awesome to have a little photo booth of SGRT, so the head and neck patient who often has to have adaptation at least a couple of times during treatment can get surface-guided 3D captures before on table, and we can let the physician know nothing’s changed since yesterday. Don’t even come to the machine. We’re going to treat the normal plan. But as you have this metric that you’re tracking every day because it’s non-ionizing, you can get that surface every day. If you get that surface every day and finally a volume trigger is tripped, then you say, “Okay, today, we would like you to come to the machine because there’s a high probability that we may have to adapt this patient today.” So you’re saving the patient additional time on the table by telling the physician, “Hey, this may be an adaptation day,” versus getting on the table and every day having to be there making the call, “Okay, just use yesterday’s plan and then go move on.” This could be a throughput thing or a workflow thing that could be added into the workflow that’s not on table, it’s pre-table. And so that’s a future adaptation for adaptive radiotherapy.

Protons, as I said, more small form protons are becoming reasonably affordable. Affordable in my wife’s sense of affordable, she saves me money. Only $26 million, but it’s not $80 million, so I saved 60-some million dollars or 50-some million dollars. But SGRT is very important for protons, and as more and more protons are out there, I think SGRT should be the standard of care for protons. That’s my opinion, I guess. I’m a bashed proselytizer for SGRT. But in this case, we all know the Bragg peak, the discrepancies, the small millimeter discrepancies that can lead to centimeters of dose discrepancy. But there are operational problems. Gantries are slow. Treatments are long. We have limited imaging on some of these gantries, so not all proton systems have a three-dimensional imaging system within the vault. They’re relying on planar imaging. And so SGRT can bring some benefits to these workflows that they just don’t have available to them because of the geometry of the room that we’re dealing with. So you can look at continuous gantry motion monitoring. You can look at patient positioning. You can look at collision mapping or clearance mapping, sorry, Thomas, wherever you are. But you also have operational problems with those. And so you have to think about the motion complexity gantry for protons is very different than a CRM Linac or than a Halcyon. You have these complex six-dimensional couches that have deterministic couch positions, but they are very heavily dependent on the starting conditions. So you have a knuckle under the couch, and that knuckle might be in different orientations depending on if you’re moving to position B from start position A or start position C. So as you move that couch, you have deterministic positions, but they’re all nodal dependent. So those models are a little bit more complex than what we’re seeing in MapRT right now.

Automation and real-time safety, we all know about wrong patient prevention. I think everybody should have the facial recognition system. That’s just my opinion. Again, take it for whatever it is. It’s free. It’s usually worth what you’ve paid for it. But the facial recognition system is incredibly robust now. I know it had a predecessor whose name we shall not mention. Joe’s laughing at me right now already. He’s like, “Please, God, don’t say the name.” But the patient ID system is absolutely fantastic. You can see it at a desite this evening. Tighter, smarter tolerances. There’s plenty of papers now about using SGRT data to predict PTV margins, and then therapist in the loop instead of therapist being the loop. So anything we’re doing checks with now that could be automated should be automated. And so the future should be a more automated approach, but it should be things that, not new checks, but automating or continuously running the checks that we already trust. So it’s not something we’re trying to add additional checks, but we’re trying to make the checks that therapists have to do very automated so that they can be focusing on patient care at the machine.

And so planning system and OIS integration, this was a huge wish list of people who have talked to me for years on some of this stuff. I’m just going to leave this here. There’s the OIS integration, I think more and more integration. The one I will harp on is this HIS/RIS integration at the CT sim. We have used DICOM for a very, very long time. CTs will run off of schedules using HIS/RISes and DICOM worklists. The fact that I’m still fat-fingering medical record numbers into my SimRT system makes me want to jump off the parking garage every day. If I cannot get a 4D CT sim VXP file over because the mismatch of the medical record number one more time, I think I will go insane. But there are some low-hanging fruit for the future that we could easily make these systems more integrated together, integrating these systems a little bit tighter. And then what comes next, this is just purely speculation, so we’re just going to get a little crazy on some of these. These are some love projects from some of our folks in AdventHealth in Colorado. Osteoarthritis is becoming a huge thing in our clinics. I don’t know. So I see some people already nodding, yes, we’re seeing more and more of this. I don’t know how you guys feel about your osteoarthritis hand sims. I loathe them with a fiery passion of a thousand suns, because we do silly things. We have these little old women coming in and saying, “I need my hands treated,” and the first thing we’ll do is like, “You know what we’re going to do? We’re going to have you lay Superman on the CT, so we can CT your hands with your hands above your head on this carbon fiber diving board.” She’s got arthritis, guys. It’s kind of a ridiculous thing. So this is how I feel. This is just to end the day on a light mood. This is how our sims go. My fingers hurt. What’s that? My fingers hurt. Oh, well. Now your back’s going to hurt because you just pulled landscaping duty. Anybody else’s fingers hurt? I didn’t think so. Yeah. So if that strikes a chord with you on how you feel when you do osteoarthritis sims, that is osteoarthritis sims at my clinic. So what we would like to do is reimagine how this works in the future. And so what we would like to do is do optical sims. So this is a MapRT capture of a hand, and we’re running in our scripted software. We’re essentially doing an optical sim of this patient. So we’re lining up the hand that we captured optically, using the cameras. We’re setting an isocenter, and we’re going to export this hand as a surface for treatment planning. We can then convert this hand, this three-dimensional mesh, into a synthetic CT. We can then use that CT for planning. So now we have a representation of the hand, but the patient never had to lay on the couch. They never even had to have any radiation exposure. They just had an optical sim. You can also use a much more accurate camera. So this is a very, very small, same type of technology, surface camera. This is my 15-year-old son’s hand. My wife does not let me irradiate him, so don’t call Child Protective Services on me. This is his hand, and then this is his synthetic CT for his osteoarthritis plan. I can see his fingernails. I can block the nail beds. I can do all the same things I would want to do with a CT, but I can do this completely without exposing him to radiation, as far as my wife knows. We can then line him up. We can set him up on the treatment machine just like any other patient now because we have the synthetic CT in the planning system. We can line him up with AlignRT, get him ready for treatment. We can actually take an image. I didn’t do this, but you can take an image of the person and make sure that you agree with the block. You can then use the DoseRT system to make sure that the coverage, now this is a live patient. This is not my son. The coverage over the wrist is what you would prescribe. And the nice thing about this workflow is this is the first time the patient has received radiation. There’s absolutely no radiation to this patient because they have a benign condition. They don’t have cancer. And so we have completely adapted this plan to an individual without ever having to expose them, put them in an uncomfortable situation where they have to lay face down on a carbon fiber plate because her fingers hurt.

You then when you get done, you can see the absolute workflow for treatment of both hands using the OIS module. You can see it all documented out. And this patient has a complete medical record number. You can bill this actually level three if you want because it’s two isocenters, and I was told I can do whatever I want. I was in that seminar this morning. So I’m billing for multi-iso and image tracking. But you can do this, and so I’ve not done anything incredibly earth-shattering here, but I have reimagined how that sim process should look for a benign condition within our clinic. We also have a project of love by one of my physicians is patient lymphedema. This is something that our patients really do struggle with in radiation oncology specifically. If you are irradiating nodal regions and you have prior lymphatic disruption via surgery, resections, dissections, this is a real thing. The detection struggles with lymphedema clinics is they usually don’t have baseline measurements. They lack consistent tools to do so, limited standardization of how these measurements are done. And these patients suffer for that. And the lymphedema clinics do not make money. Unfortunately, they cannot afford a lot of the tools that are offered to them are extremely expensive subscriptions. And so this is something where maybe SGRT can jump in in the future because the main challenges are we have no pre-treatment baseline. We’re seeing these patients every day in radiation oncology. We have measurement methods that are variable, inconsistent protocols for those measurements, and limited access to objective tools to analyze those measurements. And why it matters is because if we don’t catch this early, it’s hard to reverse these types of things, and you subject this patient to a longer-term risk of chronic swelling, infection, and it’s a hard-to-manage thing after it’s kind of gotten out of the gate. And so you’d like to be able to use a tool to actually identify this and refer these people into lymphedema clinics for therapy earlier on. A lot of the tools are very archaic. The circumferential tape method is most common, where you either lay the arm or the limb on a grid and then you’re measuring every four to five centimeters. You’re estimating the volume by assuming there’s a cylinder between each mark. And so you get an overall grid, and if the volume changes by 10% then maybe that lymphedema is setting in and you should refer them out. You can also put indelible marks on their arms so as they come back, you have a little bit more consistent location for each of those measurements. Water displacement is considered the gold standard, but you can imagine how fun that is trying to take a head and neck patient who may have edema in their neck and try to stand them on their head in a bucket of water. Probably doesn’t go super well. The arms, legs, that’s probably also a mess. Periometry is actually super interesting. As a physicist, I could probably dork on that for a while. But it’s an infrared light that allows you to get a contoured estimate volume. The bioimpedance is also another one, but extremely, extremely expensive for these clinics, where it’s measuring the impedance through the limb, using that as a surrogate for the amount of fluid around each cell. And then obviously there’s image testing, which is the most accurate, but unbelievably expensive, and insurance doesn’t like to track lymphedema once a week with an MRI. So, these are the things that are available. These are the things that we have tried. So we took our therapists, and we measured their arms with these scanning cameras, for getting a surface mesh just like you would for SGRT. And then it looks like this is not updating, so I don’t know why the video down here is not running. But essentially, you take measurements on this surface mesh. So you can actually use a geodesic measurement tool and actually measure this limb, and the scan takes maybe two to three minutes. And so if they’re already there for treatment, you can scan them in an exam room, and you can have these measurements repeatably over weeks of time. You can then use the tool like we just looked at, and since we’re looking for volume, why take the measurements and do all the stupid estimation? You could actually convert this into a synthetic CT, actually auto-contour it, auto-fuse it to last week’s, and just check the volume change from week to week. And this is a totally doable thing where you can automate this process probably very easily. This is me playing with Python code in my spare time. So someone much smarter than me could probably make something in the SGRT realm. Joe, I’m already calling it. If you make it, I get 1% of whatever you sell. But if you do something like this, you can imagine where surface guidance is now expanding beyond just on-table things to quality of life metrics for our patients. So, if you take nothing else out of the last 30 minutes, these are the things I wish you’d take away into the future. SGR is becoming a workflow platform. It is a treatment infrastructure. Right now it is kind of siloed tools, but it is becoming a workflow, in reality, in our clinics. To anchor the cases that you want to look at in your clinic, your anchor cases are your test cases. So if you are a clinic that is doing a bunch of maskless head and neck, or you’re a case that does DIBH breast, or you’re doing pediatric SBRT, if those cases are going well, then those become your anchor cases and you move on from there. If they are not going well, the first thing you need to do is use the tools more effectively and address the limitations in your workflow. Once you’ve kind of dialed in your workflows, you’re now ready to go on into the future and have that integrated workflow platform, and integrate more tools into that workflow. And the last one’s mostly for the vendors, but for everyone else too, is that the future is integration, it’s not invention. We keep having more and more invention. We have more and more amazing tools, and I love to play with them, and I will always be there to nerd out with whoever wants to give me a tool to play with. But unfortunately, I also work in clinic—not unfortunately, I shouldn’t say it that way. That sounds terrible, doesn’t it? Unfortunately, I have to deal with cancer patients. Unfortunately, we live in a reality where these things need to be practical. They need to be workflow integrated where I’m not dealing with crashing computers, or I’m not dealing with the same system not talking to itself. And the more and more we can integrate tools within SIM and tools within treatment where they speak with one another, but also kind of integrate with the other systems that we’re working with, that will be the future over, I think, the next decade. So, don’t hold me to it, though, because it could be totally something different. So that whole last 30 minutes could’ve been a waste of time. So but that’ll be it.

 

 

 

*This transcript has been AI-generated. Contact us at secretary@sgrt.org if there are any issues.

Alisha Chlebik, RT(T)
Senior Radiation Therapist
Children’s Hospital Los Angeles, USA

Transcript

So my talk today is on implementing AlignRT and MapRT into a clinical workflow. So I have no conflicts of interest to disclose. Some of the objectives we’re going to talk about today is to describe a multidisciplinary implementation strategy that we use at CHLA to successfully integrate AlignRT and MapRT into the clinical workflow, evaluate the positive and negative impacts of introducing new SGRT technologies on the radiation therapy workflow, identify common challenges encountered during implementation, which includes staff buy-in, training, time constraints, and describe strategies to overcome these, and also compare different implementation approaches and discuss how strategies may vary across different clinics.

So Children’s Hospital Los Angeles had implemented AlignRT into the clinical practice and achieved a completely markerless workflow within nine months of the initial implementation. This was back in 2012, and then we followed the introduction of MapRT into the clinical workflow in 2015, and we eliminated the need for physical dry runs and expanded the clinical use of non-coplanar fields for complex treatments. The implementation of AlignRT and MapRT at CHLA followed a multidisciplinary team-based approach. Input and feedback from therapists, physicists, and physicians were incorporated throughout the process, and that helped us result in a more effective and sustainable application of surface guided radiation therapy or SGRT.

So these are just a couple pictures of the MapRT cameras that are in our simulation room. And so MapRT is installed in the simulation room in a two-camera configuration, and it uses 3D surface captures of the patient and its immobilization devices, along with the dedicated software to be able to identify and avoid unsafe gantry/couch configurations. So it is a patient-specific surface data which predicts more accurately than a generic database. And again, MapRT was implemented for us in 2025 into clinical use. And we use MapRT on all cases, regardless of the complexity. And so for us, the use of MapRT expanded the clinical use of non-coplanar fields for complex treatments by allowing for more complex beam arrangements. It provides a significantly higher confidence during treatment planning and delivery by accurately identifying potential patient and machine collision risks.

So these are just a couple pictures of the MapRT software. I purposely chose more adult-like patients, so you guys could imagine what it would be like if you guys were using it as well. So I’ll start with this one over here. This is a patient that we had that had to be, you can see, tilted up. They were having some breathing issues, so we tilted them up to be able to breathe better, and then we were able to use MapRT to verify that it would not collide during the treatment. And this is not standard for us. Usually, we try to have our patients lay flat. The middle is just a picture of a collision. I purposely made it collide so you could see how obvious it is that there would be a collision. And then you can see in this picture as well, you can see there’s a couch kick and a gantry kick. And in this, you can see that if we had used a database or didn’t have the patient available to see, as a therapist doing a dry run or even a physicist, you might say it clears. However, let’s say a patient had a larger belly or there was something sticking out, that would not have been identified prior to MapRT. So those are very helpful for us because a dry run cannot capture what if you don’t have a patient in. So sometimes prior to MapRT, we physically would lay get up on the table, see if it would work, just to test it prior to the patient coming.

During simulation, some patients require positioning that falls outside of the standard setup due to anatomy, disease location, immobilization devices, or comfort considerations. So these atypical positions can really increase the risk of gantry, couch, or accessory collisions if they are not evaluated carefully. And so MapRT provides tools to assess clearance and collision risk at multiple stages of the workflow. Clearance can be evaluated by the therapist prior to even scanning the patient, using in-room software to ensure that the proposed setup is safe. Typically, if you’re going to do a setup like these, these are the emergency cases or the cases that are in pain or something that’s a little bit different than your standard, so they’re a little bit more stressful. So we found that having these… Sorry, I’ll go back. Having that in there gives us also that assurance that however we simulate them, we will also be able to treat them. And then MapRT also allows a user to apply a configurable buffer within the software, and that accounts for the expected daily setup shifts and variations in patient positions to ensure collision-free treatment. So you might have a perfect plan that looks great, but then when you bring the patient into the table, let’s say they’ve moved one cm or there’s a couch roll or something, you can actually allow MapRT to put this in, so you can take that into consideration. For us, we have a six-dof couch, which having that extra buffer helps us because then we’re able to see, like if we were to apply a one-degree couch kick, would it still collide, or are we still clear?

So this is a patient picture of what we were setting up. You can see right here their arm is up, and then their other arm was down. We were trying to treat in the lung. And so you can actually see you could get the gantry closer, and if we had just simulated them, we may not have known that ahead of time. You can actually, as a therapist, go into the MapRT setup and if you know, okay, I want to treat at a gantry angle of, let’s say, 20 and the couch at 10, for whatever reason. Let’s say that’s your standard setup for something, a breast patient with their arm up. You can actually go into the software and find it and see if it’ll collide or not, and find if your arm needs to go further up or further down. We typically don’t do that, but it is something that’s available. We don’t have a lot of cases where the arms are up like this, but it is available.

And so some of the benefits of MapRT for us is it’s eliminated the need for physical dry runs that are required by a therapist prior to treatment. For those that run a very tight schedule, you don’t have a lot of time for extra dry runs, even if it’s only five, 10 minutes. Or physics says, “Hey, can you check one gantry angle for me?” You still have to go in the room, takes at least five to 10 minutes. With MapRT, you can take that out, and then you can just use it from the software. And so this workflow modification allows therapists to complete new start chart QA independent of machine availability. So again, at busier centers, this is a huge time saving. Implementation of MapRT had a negligible impact to both therapists as well as physics and dosimetry workflow.

So for a therapist during the simulation process, we create our immobilization device. We position the patient. We turn on MapRT. It adds maybe two to three minutes tops. It’s just a couple quick clicks, and I have a couple captures to show you what that’s like. The simulation therapist captures an image, multiple images if necessary, if it’s a little more complex. You merge them into a final surface, select Finish, and you’re done. Two to three minutes is being very generous. I would say adds maybe a minute tops, if that. The planning process, it just requires an export to a MapRT software to check for those collisions. It’s a little more than that, but I’ll let our physicists talk about them later. By shifting collision evaluation to a software-based work, MapRT supports safe planning practices while preserving valuable machine availability for patient care. Again, we’re not having to take these extra slots now to do dry runs. Therapists aren’t having to stay late to check them. Physics isn’t needing the machine at any point. It’s been huge for us.

And so these are just pictures, if you were a therapist, what you might see. And so when you take your first capture—oh, sorry, it’s on this side. You’ll take a capture of the room. I just put the plate on so you guys could see it, and you’ll just select two little dots, and you hit Generate Setup Surface. Simple as that. And then if you want to take a second one, you can move the couch along, do a second one, hit Capture Setup. And then you’ll end up with—this is again, just the phantom plate—but you’ll end up with completed images, and then you’ll select Finish. If there are holes in it, you can see there’s a little bit right here, but let’s say if it was bigger, you can move the table in and out to fully capture. So if you’re doing a breast setup and the arm was up, but you were closer to the CT, you can bring the table out, capture, and then you’ll get a full capture of the arm and everything else that’s included.

And so this is just the MapRT software real quick for you guys to see. You just select the patient and how you want to treat them. There’s a whole lot of different things that can be customized to your clinic, and then it comes up with some software. And I just selected this one. So you can move the gantry however you want by dragging this point. So you could see where it would collide and where it might not. And then you can see the gantry angle. It’ll actually give you the gantry and the couch angle. So if you were doing planning, you could decide what those might be.

So some quick tips for MapRT. As a therapist, when they wanted to introduce new technology, once again, we were like: We don’t have time. We’re pretty busy. I don’t know how this is going to work. Turns out it was pretty simple for us. Warm-up is one to two minutes. Actual treatment is one to two minutes, and then we don’t have to do dry runs, which I keep repeating myself, but it is huge as a therapist. So some of the things that we found that can be a little bit tricky is when you’re merging the data sets. There’s an outermost CT travel table limit, where if you go too far out, those white dots are no longer visible, and you won’t be able to take a capture. So what we did, we added a reference line to the end of the table that indicates the maximum allowable position where the camera can still visualize the white dots for registration, so you don’t even have to think about it. And I have a picture in one second.

Also, objects and people can block the camera system, so always double-check before you take. I work at a children’s hospital. Sometimes we have anesthesia, so we’ll just tell everyone, “Hey, go to the back corner.” They’ll go stand there for 30 seconds. We take a couple captures. We’ve taken them with people in the way. It really hasn’t changed that much. As long as you look at that final merge surface and it doesn’t have any holes, you’re good to go. Also, a big thing that we found is make sure that there are no blankets or clothing or anything that is blocking it because it could be interpreted by the system as a collision, even though it’s just a blanket. So if you’re covering the patient and it kind of bulges up, it’s actually going to think that’s a patient. So what we do is routinely before we take a capture, move everything out of the way as if we were going to do a treatment. Anything bulky, we just take out of the way so it doesn’t later say you’re having a collision even though it technically was not there.

So this is our handy little mark that we made. Here it is, sorry. So I didn’t want to get in trouble, so I used a piece of paper tape first, and then literally just brought the CT out and drew a line. And you can see it really merges in, and the paper tape doesn’t get up or down. But now you know when I’m just releasing the table, I go exactly to this point, and I know exactly how far to go. Because one of the frustrating things in the beginning is you bring the table all the way out, you couldn’t find it. And so as a therapist, we said, “How can we make this faster?” We just made a little mark. You could do it however you wanted, but tape, nobody got mad at, so we did that.

Okay. So the warm-up, this kind of includes both of it, but for AlignRT and MapRT, it adds three to five minutes daily for QA. And again, this is tops. If you’re still learning, it doesn’t really take that long. So AlignRT requires a daily setup with the plate. We also added an extra daily warm-up set, which I’ll show in a second, that we wanted to check that when the tolerance is out, so it’s red, that the beam actually shuts off, and we want to practice that on a patient every day. Also, a quick tip on here, you can see on the picture for MapRT, for those that have it, you do a quick capture, you move the table in 250, and then you recapture. So what I did was—it’s kind of hard to… oh, sorry, good, go back. There’s a little dot, it’s probably hard to see, right here, and that indicates right around that 250 value. So I literally, I’ll set up to the zero. I zero the couch, go to the dot, and I should be pretty close to 250 and fine tune it, just to make it faster for us. Again, even if you didn’t do that, it still does not take very long.

So the AlignRT warm-up consists of the daily plate, and we added one additional test. Part of this was due to APEX accreditation. They were asking about it, so we just came up with something on our own. So we added an additional test that verifies the functional integration between AlignRT with the linear accelerator, ensuring that the motion outside of tolerance correctly triggers a beam hold interlock, providing an added layer of safety. It’s not super high tech. So during warm-up, the therapist positions a motion device, tracking, which is our old Varian RPM that we don’t use anymore, and then we just found—this is actually from Astro—it’s just like a stress ball that was a CT. It was still not picking up everything great, so working at Children’s Hospital, I found a little rubber duck that we added to it, and we just taped them all together. So now when the motion goes, it’s very easy for AlignRT to set up.

And you can see on here, this is like… sorry. Before we capture every morning, you set it up wherever, take a quick capture, then you turn on the device. It measures, you go to around 100 MU, and when it comes out of tolerance, should shut the beam off, and then we move forward. So it’s 100 MU, so it’s maybe a two-minute extra set, and then it verifies that every morning. We were trying other things first. So we did find that if you utilize high-contrast white objects, it works much better. So we didn’t purchase anything to do this test. So you can look around your clinic, see what you want, but it was pretty straightforward.

So then for AlignRT implementation, that one was a little bit longer because we were going from marked setups. We didn’t use tattoo, but we did use Sharpies to mark less. During the implementation of AlignRT, we actually collected clinical data before, during, and after integration of SGRT. Metrics evaluated included our patient shift magnitudes, the frequency of repeat imaging, and overall patient setup time. All of these were important working in pediatrics, especially when they’re under anesthesia. We wanted it to be faster, but also still safe. So the data was used to assess the workflow efficiency as well as the clinical impact.

We started small. Everything that we did were in small chunks, because we felt like if we took too big of a bite, we were not going to be as ready to implement, so we started small. So what we did, we just had a printed spreadsheet we kept next to the machine. We actually set up first to the patient marks, then we imaged, and then after we applied shifts, what we would then do is turn on AlignRT and record the data of the shifts. So that gave us the magnitude of shifts from AlignRT into imaging. That way, in the beginning, we were just going with our normal workflow, we weren’t adding a lot of extra steps. This is just an example of data—it’s not real data, sorry, guys. But you can see we found that when we were doing it, the data did show that it was comparable or less than; sorry. So we then moved forward.

As a therapist, this kind of talked toward me, was initial reluctance. At the time, I did not want to. So there could be initial reluctance to transition to AlignRT-only setup, leading to continued reliance on standard skin marks. So we took our time, and this approach was maintained until it became evident that the shifts between the CBCTs and AlignRT were consistently smaller magnitude, which gave us the increased confidence to use AlignRT only. So after that, that was maybe about two to three weeks, and then we moved over. We transitioned to AlignRT-only setup. We did, for a short time, retain the skin marks as backup until we regained confidence in the system. Shift data continued to be recorded, and then once as a multidisciplinary team, we reached consensus, skin markings at simulation were discontinued. So all of this, I would say, was less than six months. It took us nine months total because we do CSIs frequently, and we held onto those marks for a little bit longer. But after nine months, we no longer mark any of our patients, including electron or keloids as well.

Like I said before, therapists were the most hesitant to remove any marking on patients. This was our comfort item. Sometimes people say, “Just try it. Just try it.” And as like Mama Bear, we’re like, “No, no, no, we need to do that.” But once we saw the data, we go, “Okay, this is pretty good.” And after positive feedback from patients and not having to keep their marks, seeing the minimal shifts and less imaging that we had to do, we felt confident in removing all the marks.

Again, so it took us approximately nine months; that’s including CSI. We implemented it back in 2012. At that time, there were no other pediatric centers or people using it in pediatrics, so we had to develop our own workflow and tailor it to the custom needs of CHLA. So that did add a little bit of time and complexity to the implementation strategy or process. So although the underlying technology is the same for both adult and pediatric patients, the application in pediatrics presents unique considerations. However, once the initial implementation changes were overcome, it became clear that SGRT provided a greater range of benefits than we as therapists and the whole team originally expected.

So some of the examples of differences or changes that we had to encounter were, we had to change some of our ROIs. For anesthesia patients, we had to move their monitors, uncovering them, or undoing the blankets or just moving things. All of these, again, after a couple of weeks, we figured out how to do it, and now smooth sailing. But that initial bump was a little bit harder. Again, most of ours were six months. CSI added a little bit longer because they were a multi-isocenter. However, CSI patients, once we actually implemented them, we’re getting them down to 30 to 40 minutes for CSIs, even the adult-size CSIs.

Concurrent installation and implementation of TrueBeam and AlignRT required staff to undergo training on two new technologies and proved to be a bit overwhelming in the beginning. And so one of the things that we learned from that was to maybe just try one at a time or to focus on one first. After we gained confidence in the TrueBeam, then we added AlignRT and began collecting data, which included the shift magnitudes, frequency of repeat imaging, and patient setup time. Again, we did this in a phased approach because, at the time, we did not want to add too much extra workload to the therapist, because we didn’t have a lot of extra time. We did it phased and that seemed to be really helpful. After we analyzed the shift magnitudes, we expanded the data to include repeat imaging frequency, overall patient setup times, and the comparison between all those. As therapists, as we became more familiar with it, we saw a decrease in the metrics as well. So over time, they kept getting smaller and smaller.

Throughout the learning and implementation process, several key factors were identified as critical to the success of adoption of new technology, which includes AlignRT or SGRT. These included early education prior to product installation, strong staff buy-in, identification of clinical champions, a small rollout rather than a broad implementation, and direct observation of positive patient impacts. Those all really helped us. If staff members have a basic knowledge of SGRT prior to installation through online learning modules or in-person training, it’ll greatly also help your implementation. Staff buy-in is critical for all team members to have buy-in. I hear from different sites that sometimes a physician says, “Just do it.” That doesn’t always work for therapists when they have a busy workflow. So sometimes having extra champions like we talked about earlier, or having their buy-in or having them see what the differences could be. So therapists may be resistant at first to new technology because it’s going to impact their workflow, and many centers don’t have a lot of flexibility in their time. Twelve minutes in, out, in, out, and I know some places if you get behind, you’re never going to catch up. So saying, “Just add this in,” while seemingly small, can have a huge impact.

Champion or super users: if you can identify staff that are willing to serve as super users to support adoption training and troubleshooting, this will greatly help the therapist as well. It can identify possible issues that maybe other people weren’t thinking of, and you can help find solutions when necessary. Identifying knowledgeable, well-respected therapists within the group can also help increase your buy-in.

Small incremental rollouts: this was huge for us. It gave us time as staff to learn the new technology before implementing it to all patients. So due to short staffing, strict schedules, implementing a new technology such as SGRT for all patients at once can be challenging. So starting with a small number and expanding as staff become more confident is effective. We began with just chest and abdomen, and then we went to the next extremity, to CSI and pelvis, and now we do it on every patient from brain all the way to CSIs, TBIs—everything gets it now. A stepwise approach was used, adding new body sites once staff demonstrated confidence with the previous one.

Direct observation of positive patient outcomes encouraged therapists to continue implementation, which played a key role in our early success and improving the overall buy-in of therapists. We found patients did not like to have visible marks on their skin, and they did not like to keep them in place during treatment. I think that’s pretty standard across the board for every patient. Also, direct monitoring during treatment made it possible for us to safely lower the age of anesthesia or the age a patient required anesthesia because now we could actually quantify how much they were moving.

Challenges associated with AlignRT and MapRT implementation include the staff hesitancy, a steep learning curve, mostly for AlignRT, and increased setup times during the early adoptions. Resistance to change and unfamiliarity with surface-guided radiation therapy workflow contributed to the slower uptake, while additional training requirements and workflow adjustments temporarily affected our efficiency. However, these challenges diminished as staff gained experience and confidence in the system. And with all that being said, we work much faster now than we did prior. But there is that when you first start it, you might see a little bit of slowdown, but it gets better.

So given an already demanding schedule for treatments, therapists found it difficult to incorporate the additional time required per patient during the early stages. So we would select a small number of patients and add five minutes to their treatment schedule. I know that’s not always possible, but if you can pick one or two, expand their treatment, that gives you a little time, and it kind of avoids the stress. I know, not always possible. We also had some hesitancy because we were one of the early adopters, so it took us a little longer, as well as we already kind of talked about the additional time, which I know I’m repeating myself, but it does have an impact.

Just some quick tips while we’re finishing up. So I don’t know how many of you guys have the remote system that came with a lanyard. We love the remote, didn’t love the lanyard, and our computer for it is on the other side of the room. So what we did is I took a little Velcro, and I put some Velcro on the back of it, and it’s just on the side of our TrueBeam. So now I can just reach over, hit play, take a capture, put it back, and we’re good to go. So again, just little minor adjustments, depending on what your room looks like, can have a huge impact. So one therapist can easily reach a computer, and one therapist can reach the remote. Have regular trainings, check your Vision RT contract because I don’t know how that all works, but I know we have yearly training that we can use. Also, any new staff or even if we have students come through, we just had a practicum one, we just throw on the phantom and say, “Have fun. Practice because practice makes perfect.” So we’ll just let them do whatever they want on Emily or whatever phantom you have.

Conclusion is just we’ve successfully implemented AlignRT in the clinical workflow through a collaborative team-based approach. While challenges were encountered, the multidisciplinary team ultimately developed a workflow that best met the needs of our institution.

*This transcript has been AI-generated. Contact us at secretary@sgrt.org if there are any issues. 

Neil Worlikar, MS, DABR
Director of Medical Physics
Advocate Health – Midwest Region, USA

Transcript

Very glad to be here. And I will be talking on implementing dose visualization, which I really believe improves patient safety as well as plan quality in radiation therapy. First, my acknowledgments and contributors. I wouldn’t be here without the support of my physics team, who actively use this technology in many of our clinics. I don’t have any conflicts of interest. I am so passionate about DoseRT that my organization paid for me to be here today. Also wanting to recognize one of our medical physics residents, Ila Farhang, who contributed to this talk as well.

Advocate Healthcare has sites in North Carolina, Georgia, as well as in the Midwest, where I am primarily based, in Illinois and Wisconsin. We currently have five systems of DoseRT, two that are implemented in our Illinois market, two that are implemented in our Wisconsin market, as well as one in the atrium market. We are pending installation of three systems at our major cancer center in Milwaukee at Aurora St. Luke’s.

And really, I wanted to start by talking about our interest in DoseRT. We have been AlignRT customers since 2013. We have it at nearly every one of our system installations. And we were very excited when we heard about the technology, and even the concept of Cherenkov radiation at ASTRO. We feel as though it really is analogous to a seatbelt. You wear a seatbelt every time you drive a car. You really don’t notice it until you need it. I know I was involved in a pretty bad car accident about 30 years ago, and a seatbelt saved my life. And so I do think that as we look and evaluate DoseRT, that is really its benefit of showing you where the radiation dose is going.

It also aligns with our internal cancer service line strategy of really providing care to patients in a compassionate way to the loved one standard. And that’s very important to us. Many of us receive our own healthcare within our system. Many of us have friends and family that also receive healthcare within our system. And so we really always try to do the best possible job we can. And I think we do a really good job with patient treatment, but it can always be better, and good is the enemy of great. And so we are constantly looking to iteratively improve our processes.

The strong advantages of DoseRT qualitatively is the enhanced visibility and confidence that we gain in treatment delivery. What we see as the future, quantitatively, and Dr. Gladstone spoke a little bit about this yesterday, is the potential for measuring dose as the technology matures.

So our installation experience was very positive with VisionRT, but there are some elements that are outside or have been outside of VisionRT’s support. One of those is lighting. So if you are thinking about implementing DoseRT, you really need to think carefully about your lighting. So in August, we implemented DoseRT, and with one of our cameras, we were able to visualize dose. On the other camera, we were not. Through a lot of investigation, we found that that had to do with the UV light filtering on some of our lighting.

Additionally, every vault that I have seen is very different, and we have several different vault varieties. We have what I would say is a traditional vault. We also have a garden vault that is open to the outside. So I have a picture of it; it’s covered in snow. Not the greatest idea in an environment where you have all the seasons, although that natural ambient light is something we did for the patients, and we do have natural plants that we put in the springtime in that area.

So looking at our traditional vault, we have a lot of elements in this room. First, to highlight, we have two laser systems that are set for lateral positioning, really listening to our therapists wanting to have an ergonomic laser that’s 30 cm below to help with any kind of rotational and setup of the patients. Additionally, also keeping our therapists in mind, we have an Argo lift for patients not to grab onto therapists, but to grab onto that device. And we have two dual in-room monitors looking at ergonomics. Depending on which side of the couch you’re standing on, you can still see the monitors. That being said, there’s a lot going on in this room. We are not typically putting in any of those kind of skylights or those different items. When we first implemented the track, it was hitting the DoseRT camera, and then when we do treatment, part of our procedure is to keep that Argo lift in a different area.

I will also say that DoseRT is susceptible to red wavelength light, so we have green lasers, and I highly recommend that for anybody that is purchasing lasers. We’ve tried blue, but green is really great. Red would have an impact. Additionally, we had installed light filtering on each of these can lights, and it’s kind of hard to see, but there’s a little bit more purplish light from this light, whereas this is more white. This came from the same manufacturer, but different batches of the UV filtering. And so what we needed to do is really work with getting the filtering that worked the best for our implementation.

And like I said, we have the garden, so you can kind of see a little bit of snow. We have some flowers. When we originally put this vault in, we did purchase AlignRT, and the calibrations for that system worked really well. We were not thinking about DoseRT at the time, several years ago, and it was pre-DoseRT. And so we have now blinds that we bring in during treatment with DoseRT because you really do need a dark environment for that treatment, but it is a feature that we still have in the room and utilize. But I’ve had to modify our workflow a little bit just because of the ambient lighting and learning things from the installation from that perspective.

Some tips and best practices: you always want to turn off the ODI. That’s part of the procedure for us. It is not something that our therapists always do, but that would be key in terms of setup. I think looking at some of the site visits and what folks at Atrium and others are doing with setup of patients using postural video, I think really helps with that. Using AlignRT for virtual SSDs, the ODI is not necessarily needed. We do have some older vaults that have red lasers, but that would be problematic with the DoseRT.

The other element for us is there’s elements in the VisionRT system and the DoseRT system which are great. We have not only one set of in-room monitors, we have dual in-room monitors. So we had to install a switch to turn off the power to these devices to darken the room, really to get the best possible DoseRT images. Incidentally, as we look at adoption across many of our sites, some of our therapists who do rotate from a system perspective don’t like how necessarily dark the vault has to be for DoseRT, but there is a future solution for that that I will touch upon.

So probably the most important and best slide in my presentation in terms of DoseRT is with the ODI. If you don’t turn it off and you have the white light ODI on during treatment, this is what DoseRT looks like. It’s not great. What we have found, we have in-house clinical engineering support that also utilizes third-party equipment, is that there is a green light ODI which is now becoming more popular. And as you can see very faintly, that is how it appears on the DoseRT camera, and you can kind of see the line. So it doesn’t obscure the lighting as much as the white light ODI. So if I were going to get DoseRT, I would really try to have the therapist get in the practice of turning off the ODI. But I also think that this green light ODI is a great solution.

For us, early IT engagement is critical to export DoseRT reports to the network. We review it the first fraction and weekly, and a lot of times we’re using it for bolus placement and verification. Another thing that we have struggled with and look at and continue to think of is our workflow design. At one of our sites, we have all of the Varian control console equipment in one area with a therapist that we call the driver. The second therapist is really looking at the VisionRT system here, and we have the DoseRT monitor above. So they’re looking for monitoring the patient, collisions, and DoseRT information during treatment.

I think it’s very important to do some early site visits with folks that have DoseRT. I know Advent has some DoseRT systems here. And I think we had very good vendor support during our go-live. Staff feedback and buy-in is critical, and it’s a team project because, as I said earlier, some staff may not want to be in the room that’s completely dark, and you may need to make some modifications to your room and to the lighting of your room.

And presenting some clinical cases, and I think a number of folks have presented theirs as well. This one was particularly interesting and important to us with a breast treatment, a four-field breast treatment with bilateral breast being treated. So we really couldn’t have the patient turn their chin to one side or the other. We did see that during our treatment, and our therapist stopped the treatment, that the chin went into the field. So this is really the power of the system that I think you’ve seen from other institutions as well as something that we can share that we really think that it does show you quite powerfully and simply when you’re having an issue.

It does also change the way in which we evaluate plans. We have had some plans where there’s some chin dose, and I think some of the other speakers have spoken to it before, where we were looking at the 50% isodose line, but really not looking at the 20 or the 10, and can really be better planners in terms of our radiation delivery based on the input that we receive from DoseRT.

Some of our clinical cases and some of the strengths of the system: verifying the appropriate flash and setup. We see a great benefit in bolus placement as well. And we do see some limitations, particularly with skin pigmentation, camera FOV for certain sites, as well as modulated fields. So looking at the example here, we have a patient positioning error with the patient’s chin turned into the field with the correction that we could see, which quite simply, it just makes our treatments all the much better. You can see that here you have some dose, but the bolus is misplaced and then placed in the correct position.

Modulated fields can sometimes be a little bit noisy. Right prone breasts also have limitations due to the camera. And then also as we look at tattoos, that can be an issue in terms of really mapping the dose accurately. It is very highly sensitive, but requires a very good room setup. But oftentimes, the physicists, we look at the purple and we’re wondering, “Well, how much dose is it?” It’s really a relative, but not an absolute dose yet. And so it’s just a really good indication for something for us to focus on.

We see a lot of value in evaluating our SRS and SBRT plans in a side-by-side plan review versus treatment review, and looking at intrafraction motion and position variability. Ambient light and reflection is a problem, sometimes from Vaclock bags, bolus, the LINAC housing. I often joke I wish I could buy my LINAC in matte black because that would cause less issues. There is, and I’ll talk a little bit about it, an upgrade pending to improve light filtering. We are actually going to be receiving that in the next 45 days, so maybe at the next year’s talk, I could talk about that implementation as well. Because sometimes you get false positives from reflections that do not represent true dose. Some of the items in terms of the review really just display the date and time. I know that there is a software coming and an upgrade that’s going to display the patient name, which makes it a lot easier for review. So by the time you do get DoseRT and with the upgraded software, it will be better than it is today.

Talking about future optimizations, Cherenkov imaging and patient comfort: it really does require a very strong focus to lighting. I know when we’ve talked to our construction folks about it, lighting and where those air deflectors go is not always mapped out well, and we’ve stressed that it needs to be for the devices, really managing room lighting conditions to get the optimal environment, and to be able to clearly visualize and see dose. I am thinking that the BeamLight solution is going to be a vast improvement for not necessarily needing to darken the room and having the lighting all tied in to the VisionRT system. So I’m very grateful that that issue that we have seen is being resolved.

I think there are five things in radiation therapy that excite me. DoseRT is one. I think Dr. Zimmer was speaking about grid therapy is another, and spatially fractionated radiation therapy. I know we’ve had a couple cases in the past month. And just seeing all of the technology coming together, and really for the benefit of patient treatment is something that we continue to support, continue to be very enthusiastic about. And with that, I’ll take any questions. Thank you.

*This transcript has been AI-generated. Contact us at secretary@sgrt.org if there are any issues. 

Sharon M Meredith, RT(R)(T)
Radiation Therapy Supervisor
Cape Fear Valley Health, USA

Transcript

So I was excited to be able to share my experience with using the AlignRT OIS Report module to assist with active motion management documentation. I work for Cape Fear Valley Health in Fayetteville, North Carolina. We have three locations, and at each location, we use Varian TrueBeams and then AlignRT for our SGRT patients. When we first started using it, we were predominantly only using it for just a handful of our patients, the deep inspiration breath hold breast patients. But as we have grown and evolved through the years, we’ve expanded that usage to encompass all types of treatments, and so currently we utilize SGRT for the majority of everyone under treatment. Our physicians are not only wanting us to use it for alignment and positioning in the room, but also to ensure that we have and monitor the patient’s position throughout treatment so we can ensure they’re in the correct position through the entire procedure.

So a daily basic run-through of one of our procedures would be to start off by using the AlignRT Patient ID module. This uses facial recognition software to ensure we have the correct patient in the treatment room, and then we’ll verify this with the patient by having them state their name, date of birth, the site that we’re treating. And then once we place them on the table, we will press play in AlignRT so that we can get them in the correct position before we ever even step out of the room. And then once we step out, we proceed with our daily imaging, which is typically cone beam CT for almost everyone, sometimes KV and MV. Then we’ll apply the shifts and capture the position in AlignRT, which essentially zeros out the deltas, so it defines our reference position for the day. The real-time deltas are the deviation between the patient’s current surface position and the reference surface position, which was attained at the time of CT simulation. And then we will toggle beam control on, and with beam control being toggled on, if that patient moves outside of the small parameters that we have set, the beam will be paused until they’re back in that threshold again, and then we’ll continue on with treatment. And then at the end of treatment, while that patient is still in that correct treatment position, we will pause the AlignRT screen so that this correct position is accurately reflected in the SGRT report for our physicians.

So the daily SGRT report is necessary for billing purposes, for documentation purposes. It has to be approved by a physician, typically within 24 hours or before that patient’s next beam-on time. Every department has their own way of documenting and recording their SGRT treatments, and at our site for years, we had a document that was created by our physicians. This is an example of one of our old documents in which we would input that daily treatment information. So it was created in ARIA, and it would appear in a list of documents for the physician to have to go in and approve. So at the completion of treatment, after we would pause that AlignRT screen, one of the therapists would sit down and type all those values into the document. They’d have to make sure that they tagged the correct physician into the document. Then they would have to select from a drop-down menu the type of treatment that we were performing for the day, like 3D, IMRT, VMAT, SRS, SBRT, and then they would type all those values from that pause screen into that document. And although effective, it did give us a form for approval. It was not the most efficient system. It would typically take 10 to 15 seconds, probably per patient, to type all that into the document. And although 15 seconds is not a very long period of time, if you have a busy schedule, 30, 35, which I thought was busy for us until I’m hearing some people have 60 to 80 patients a day, that really can start to add up. And there would always be at least once or twice during the day where one of us would be putting our values into the document, and one of the other therapists would think we were finished and would close that screen out to move on to the next patient. We’d have to stop what we’re doing, go back into the previous patient’s chart before we can bring the next patient in, pull up that document, and finish typing everything in. So sometimes not the smoothest system. The biggest issue, though, would be human error. It’s very easy, especially if you are in a hurry and you’re trying to get everything typed in before that next patient’s set up, to perhaps type in an incorrect value or leave a negative sign off, or leave a number out or put a decimal in the wrong spot. The biggest issue I would typically find would be that the therapists sometimes would forget to tag the physician into the document. So it might not get caught until the next weekly chart check, and we’d realize we had a document sitting there that never had gotten approved, and it was because the physician was never tagged into it and didn’t know it was waiting for their approval.

So around September of this past year, we were given the opportunity to be one of the test sites for the new AlignRT OIS Report module, and we were really excited to give it a try to see if it would help to improve our workflow, and it definitely has. AlignRT has always had the ability, although we were not doing it at the time, to be able to take a screenshot, convert it into a PDF, push it into a folder, and then manually export that into the oncology information system like ARIA or Mosaic. We use ARIA. But it was always a manual process. So now with the AlignRT OIS Report module, it’s a seamless transfer of information. It occurs entirely in the background. It takes that SGRT report and converts it into the DICOM format and then pushes it into the OIS automatically at the completion of treatment. So now when we complete one of our patients’ treatment and we pause and close that AlignRT screen out, this creates a screenshot of that final pause window. It inserts into the timeline in the RT summary in ARIA, and then it creates that AlignRT report. So we’re no longer having to tag a physician into the document. They’re not having to go into a list of documents to sign off on anything. I did ask our physicians if it makes it easier for them, and they did say that, yes, it makes it a bit quicker, more streamlined. They’re not having to go to two different locations to sign off on anything. It appears alongside the images they’re reviewing every day in the offline review. The therapists, of course, love it because it’s saving them a lot of time of having to manually enter in data after every single treatment, and of course, it’s helping to eliminate the risk of human error of typing those in incorrectly.

So the AlignRT report can be tailored and customized for each facility. This is an example of one of our patient’s AlignRT reports. Perhaps there’s something in the customization of our report that another site would not want to include, or perhaps we don’t have something included in ours that another site would want to include. It has all that basic patient information, name, date of birth, medical record number, the site that we’re treating, even though I don’t think you can see that because it’s probably darkened out with patient identifiers, but it is on there. It does include the screenshot of that final pause window, which was sent over from the AlignRT screen, and also it has the total duration of time, which is from when we open that patient up in AlignRT to when we close the patient out of AlignRT. It has a monitoring session time, so it breaks it down a bit further, and that’s from when we press play in AlignRT to when we pause and close out. So for this particular patient, that’s encompassing the alignment in the room, the imaging, and then the treatment itself. It includes the statement that the AlignRT system was used to position the patient immediately prior to treatment and track the patient during treatment in 3D mode. This is the default statement, and it can actually be customized as well, and some sites are now getting the verbiage to state that the patient is being tracked with active motion management. If we capture SSDs for the day, those will be inserted into the report as well, as long as we save them to the report, and that’s one of my favorite features of AlignRT in general. I love the fact that with the click of a mouse, I can capture SSDs from multiple treatment angles. So if we get those SSDs and save them, they will be inserted also.

So this is an example of a patient monitoring graph. We do not currently have this included or configured into the layout of our report at this time. I do think it’s a really neat feature, though. A lot of sites are not including it because it does increase the length of the report considerably from what I understand. As you can see, this is just a small example of one online and it says page one of eight, so it definitely increased the length of the report. But it’s a really neat feature, and it’s actually reflecting that patient’s motion and position throughout the entire treatment. If that patient ends up moving and the beam is held due to deltas being out of tolerance, that’s reflected in the graph. So as you can see on the graph, where the red bar dips below, that represents where the deltas were outside of the tolerance, and then the yellow bar represents where the beam was held due to the deltas being out of tolerance. So it’s another option. It could be included, and it would definitely be able to show evidence of performing active motion management.

If you have a patient with multiple sites, we’ve learned that we can create an AlignRT report with screenshots from each site on a single report. The physicians do seem to like this. It’s a little bit less they’re having to sign off on, and it’s fairly easy to do. So if you have someone with, for example, two sites, at the end of your first site, you can just open up the sidebar menu on the screen, which you can access from a little arrow on the right-hand side of the screen, and just click Report Screenshot, and then you could pause, move to that next treatment site, and then at the end of that second treatment site, you could just pause and close out. And so this is going to create those screenshots and insert those into the timeline in the RT summary in ARIA, and then it’s also going to insert those into the AlignRT report. So you’d have one screenshot from each site on the single report. Now, bear in mind, this is not a full detailed report for each site. It’s just a screenshot. So if you or your physician prefers to have a full detailed report for each site, that’s also fairly easy to do. And in order to do that, if you’re treating someone with, once again, two sites, at the end of that first site, you would just simply pause, close out of AlignRT, move to the next treatment site, and then reopen AlignRT. And I know for us in ARIA, if I move to that second site, it auto-launches the correlating site anyway in AlignRT, so it’s a little bit even less that we’re having to click on. But this is going to give you a full detailed report for each site for the physician to be able to review and approve, and then as well, all that’s going to be inserted in the timeline in the RT summary in ARIA in chronological order with the timestamps. So these are some of the main highlights and the features of the AlignRT reports that I have experienced up to this point.

And in comparison with our previously used system of just simply typing the values into our SGRT document at the completion of treatment from that paused AlignRT screen, the AlignRT report that is generated with the OIS report module is a much more detailed document for our patients’ records, and as well, it provides substantiating documentation to assist with our billing justification. So with the new billing changes that we’ve seen in 2026, and with the elimination of several of our previously used codes, it’s become imperative to show justification if charging that higher treatment level charge, that 77412 charge. So performing active motion management is not only best practice for our patients to ensure that they are in the correct position throughout the entire treatment, but it’s also one of the best ways to be able to provide justification of charging that 77412 charge. Therefore, practices are trying to find the best ways of being able to show supporting documentation that they’re performing active motion management. Especially if undergoing an audit, if they are reviewing and pulling specific charges, it is crucial to be able to show not only the medical necessity of performing active motion management, but also the documentation and evidence that we have been performing active motion management for our patients.

As one way of doing this, some sites are now starting to capture screenshots after they take their imaging every day. So they do their images, apply the shifts, capture the position in AlignRT, which once again zeros those deltas out, shows the patient’s in the right position. Then they could toggle beam control on, and then open up the sidebar menu and click Report Screenshot. So it’s just one additional click. It takes just a couple of seconds, but this is going to insert that screenshot into that AlignRT report. So you’d have two screenshots in that report. You’d have the one showing from the beginning that the patient’s in the correct position at the start of treatment, and then you’d have the one that’s automatically fed through at the end, showing that the patient was in the correct position at the end of treatment as well. And if beam control is toggled on, that’s reflected in that initial screenshot, so you’d be able to see that not only was the patient in the correct position at the start of treatment and at the end of treatment, but that beam control was toggled on, therefore performing active motion management. And so it’s just another option. And then as well, all that would be inserted into the timeline in the RT summary in ARIA. So if you opened up that timeline, you’d actually have a visual layout in chronological order with the timestamps of everything we had done for that patient for the day. You’d be able to look at it and visually see this is where we did our initial imaging, and then we took that screenshot. Patient’s now in the correct position. Beam control is active. Then we did our treatment. The final screenshot, patient’s still in the correct treatment position, and then the AlignRT report.

So it would definitely be another option and helpful tool to show that we’re actively monitoring the patient’s position throughout their entire treatment. With the AlignRT OIS report module, I do feel now that we have the tools, if necessary, to be able to show supporting documentation of performing active motion management. I said in the reports themselves, we have the timestamps of that monitoring session time, which correlates with what is in our RT summary in ARIA. We have the statement that automatically states the patient’s being tracked throughout treatment, but that we can customize to state the patient’s being tracked with active motion management. We have the ability of capturing those screenshots, showing that the patient’s in the correct position at the start and at the end of treatment with beam control active. And then we even have, if we choose, the ability to be able to include in the configuration of our report that patient monitoring graph, which shows that we’re tracking that patient’s treatment throughout the entire procedure, and if that patient happens to move and the deltas are out of tolerance and therefore beam is held, that’s reflected in that as well.

So with all of these, I do feel now that we are able to show the evidence of performing active motion management and therefore the justification of that higher treatment level charge. The AlignRT OIS report module has been a very useful tool for us to help to maintain precise records, eliminate the need for someone to have to manually enter in data after each treatment, eliminated the risk of human error, so now we’re more streamlined, more efficient, more accurate, and we do have, if needed, any necessary documentation and records for reimbursement justification. So once again, thank you for giving me your time and allowing me to share my experience with the AlignRT OIS report module.

*This transcript has been AI-generated. Contact us at secretary@sgrt.org if there are any issues.